



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |
|--|--|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07K 1/00, C07H 21/04, C12P 21/06</b>   | <b>A1</b>  | <b>(11) International Publication Number:</b> <b>WO 00/06592</b><br><b>(43) International Publication Date:</b> 10 February 2000 (10.02.00) |
| <b>(21) International Application Number:</b> PCT/US99/17099<br><b>(22) International Filing Date:</b> 27 July 1999 (27.07.99)<br><br><b>(30) Priority Data:</b><br>60/094,465 28 July 1998 (28.07.98) US<br><br><b>(71) Applicants (for all designated States except US):</b> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20892 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> ZUKER, Charles, S. [US/US]; 4778 Thurston Place, San Diego, CA 92130 (US). ADLER, Jon, Elliott [US/US]; 1099 Turquoise #10, Pacific Beach, CA 92109 (US). LINDEMEIER, Juergen [DE/DE]; Franziskaneranger 2, D-59457 Werl (DE). RYBA, Nick [US/US]; 9202 Lundigen Court, Bethesda, MD 20817 (US). HOON, Mark [US/US]; 4218 Warner Street, Kensington, MD 20895 (US). | <b>(74) Agents:</b> PARENT, Annette, S. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94107 (US).<br><br><b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>With amended claims.</i> |   |
| <b>(54) Title:</b> NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN SENSORY TRANSDUCTION  |  |   |
| <b>(57) Abstract</b><br><br>The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors.   |  |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LJ | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

5 **NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED  
RECEPTOR INVOLVED IN SENSORY TRANSDUCTION**

**CROSS-REFERENCES TO RELATED APPLICATIONS**

This application claims priority to USSN 60/094,465, filed July 28, 1998,  
herein incorporated by reference in its entirety.

10 **STATEMENT AS TO FEDERALLY SPONSORED RESEARCH AND  
DEVELOPMENT**

This invention was made with government support under Grant No. 5R01  
DC03160, awarded by the National Institutes of Health. The government has certain  
15 rights in this invention.

**FIELD OF THE INVENTION**

The invention provides isolated nucleic acid and amino acid sequences of  
sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods  
20 of detecting such nucleic acids and receptors, and methods of screening for modulators of  
sensory cell specific G-protein coupled receptors.

**BACKGROUND OF THE INVENTION**

Taste transduction is one of the most sophisticated forms of  
25 chemotransduction in animals (*see, e.g., Margolskee, BioEssays* 15:645-650 (1993);  
Avenet & Lindemann, *J. Membrane Biol.* 112:1-8 (1989)). Gustatory signaling is found  
throughout the animal kingdom, from simple metazoans to the most complex of  
vertebrates; its main purpose is to provide a reliable signaling response to non-volatile  
ligands. Each of these modalities is thought to be mediated by distinct signaling pathways  
30 mediated by receptors or channels, leading to receptor cell depolarization, generation of a  
receptor or action potential, and release of neurotransmitter at gustatory afferent neuron  
synapses (*see, e.g., Roper, Ann. Rev. Neurosci.* 12:329-353 (1989)).

Mammals are believed to have five basic taste modalities: sweet, bitter, sour, salty and unami (the taste of monosodium glutamate) (*see, e.g., Kawamura & Kare, Introduction to Unami: A Basic Taste* (1987); Kinnamon & Cummings, *Ann. Rev. Physiol.* 54:715-731(1992); Lindemann, *Physiol. Rev.* 76:718-766 (1996); Stewart *et al.*, 5 *Am. J. Physiol.* 272:1-26 (1997)). Extensive psychophysical studies in humans have reported that different regions of the tongue display different gustatory preferences (*see, e.g., Hoffmann, Menchen. Arch. Path. Anat. Physiol.* 62:516-530 (1875); Bradley *et al.*, *Anatomical Record* 212: 246-249 (1985); Miller & Reedy, *Physiol. Behav.* 47:1213-1219 (1990)). Also, numerous physiological studies in animals have shown that taste receptor 10 cells may selectively respond to different tastants (*see, e.g., Akabas et al., Science* 242:1047-1050 (1988); Gilbertson *et al.*, *J. Gen. Physiol.* 100:803-24 (1992); Bernhardt *et al.*, *J. Physiol.* 490:325-336 (1996); Cummings *et al.*, *J. Neurophysiol.* 75:1256-1263 (1996)).

In mammals, taste receptor cells are assembled into taste buds that are 15 distributed into different papillae in the tongue epithelium. Circumvallate papillae, found at the very back of the tongue, contain hundreds (mice) to thousands (human) of taste buds and are particularly sensitive to bitter substances. Foliate papillae, localized to the posterior lateral edge of the tongue, contain dozens to hundreds of taste buds and are particularly sensitive to sour and bitter substances. Fungiform papillae containing a 20 single or a few taste buds are at the front of the tongue and are thought to mediate much of the sweet taste modality.

Each taste bud, depending on the species, contain 50-150 cells, including precursor cells, support cells, and taste receptor cells (*see, e.g., Lindemann, Physiol. Rev.* 76:718-766 (1996)). Receptor cells are innervated at their base by afferent nerve endings 25 that transmit information to the taste centers of the cortex through synapses in the brain stem and thalamus. Elucidating the mechanisms of taste cell signaling and information processing is critical for understanding the function, regulation, and "perception" of the sense of taste.

Although much is known about the psychophysics and physiology of taste 30 cell function, very little is known about the molecules and pathways that mediate these sensory signaling responses (reviewed by Gilbertson, *Current Opin. in Neurobiol.* 3:532-539 (1993)). Electrophysiological studies suggest that sour and salty tastants modulate taste cell function by direct entry of  $H^+$  and  $Na^+$  ions through specialized membrane channels on the apical surface of the cell. In the case of sour compounds, taste cell



depolarization is hypothesized to result from  $H^+$  blockage of  $K^+$  channels (*see, e.g.,* Kinnamon *et al.*, *Proc. Nat'l Acad. Sci. USA* 85: 7023-7027 (1988)) or activation of pH-sensitive channels (*see, e.g.,* Gilbertson *et al.*, *J. Gen. Physiol.* 100:803-24 (1992)); salt transduction may be partly mediated by the entry of  $Na^+$  via amiloride-sensitive  $Na^+$  channels (*see, e.g.,* Heck *et al.*, *Science* 223:403-405 (1984); Brand *et al.*, *Brain Res.* 207-214 (1985); Avenet *et al.*, *Nature* 331: 351-354 (1988)).

Sweet, bitter, and unami transduction are believed to be mediated by G-protein-coupled receptor (GPCR) signaling pathways (*see, e.g.,* Striem *et al.*, *Biochem. J.* 260:121-126 (1989); Chaudhari *et al.*, *J. Neurosci.* 16:3817-3826 (1996); Wong *et al.*, *Nature* 381: 796-800 (1996)). Confusingly, there are almost as many models of signaling pathways for sweet and bitter transduction as there are effector enzymes for GPCR cascades (*e.g.,* G protein subunits, cGMP phosphodiesterase, phospholipase C, adenylate cyclase; *see, e.g.,* Kinnamon & Margolskee, *Curr. Opin. Neurobiol.* 6:506-513 (1996)). However, little is known about the specific membrane receptors involved in taste transduction, or many of the individual intracellular signaling molecules activated by the individual taste transduction pathways. Identification of such molecules is important given the numerous pharmacological and food industry applications for bitter antagonists, sweet agonists, and modulators of salty and sour taste.

The identification and isolation of taste receptors (including taste ion channels), and taste signaling molecules, such as G-protein subunits and enzymes involved in signal transduction, would allow for the pharmacological and genetic modulation of taste transduction pathways. For example, availability of receptor and channel molecules would permit the screening for high affinity agonists, antagonists, inverse agonists, and modulators of taste cell activity. Such taste modulating compounds could then be used in the pharmaceutical and food industries to customize taste. In addition, such taste cell specific molecules can serve as invaluable tools in the generation of taste topographic maps that elucidate the relationship between the taste cells of the tongue and taste sensory neurons leading to taste centers in the brain.

30

## SUMMARY OF THE INVENTION

The present invention thus provides for the first time nucleic acids encoding a taste cell specific G-protein coupled receptor. These nucleic acids and the polypeptides that they encode are referred to as "GPCR-B3" for G-protein coupled

receptor ("GPCR") B3. These taste cell specific GPCRs are components of the taste transduction pathway.

In one aspect, the present invention provides an isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, the receptor comprising  
5 greater than about 70% amino acid identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. In another embodiment, the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions  
10 to the same sequence as degenerate primer sets encoding amino acid sequences selected from the group consisting of: IAWDWNGPKW (SEQ ID NO:7) and LPENYNEAKC (SEQ ID NO:8).

In another aspect, the present invention provides an isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, wherein the nucleic acid  
15 specifically hybridizes under highly stringent conditions to a nucleic acid having the sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.

In another aspect, the present invention provides an isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID  
20 NO:1, SEQ ID NO:2, or SEQ ID NO:3 wherein the nucleic acid selectively hybridizes under moderately stringent hybridization conditions to a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.

In another aspect, the present invention provides an isolated nucleic acid encoding an extracellular domain of a sensory transduction G-protein coupled receptor,  
25 the extracellular domain having greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1.

In another aspect, the present invention provides an isolated nucleic acid encoding a transmembrane domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence  
30 identity to the transmembrane domain of SEQ ID NO:1.

In another aspect, the present invention provides an isolated sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70%

amino acid sequence identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

In one embodiment, the receptor specifically binds to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In another  
5 embodiment, the receptor has G-protein coupled receptor activity. In another embodiment, the receptor has an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In another embodiment, the receptor is from a human, a rat, or a mouse.

In one aspect, the present invention provides an isolated polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor,  
10 the extracellular domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1.

In one embodiment, the polypeptide encodes the extracellular domain of SEQ ID NO:1. In another embodiment, the extracellular domain is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

15 In one aspect, the present invention provides an isolated polypeptide comprising a transmembrane domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the transmembrane domain of SEQ ID NO:1.

In one embodiment, the polypeptide encodes the transmembrane domain  
20 of SEQ ID NO:1. In another embodiment, the polypeptide further comprises a cytoplasmic domain comprising greater than about 70% amino acid identity to the cytoplasmic domain of SEQ ID NO:1. In another embodiment, the polypeptide encodes the cytoplasmic domain of SEQ ID NO:1. In another embodiment, the transmembrane domain is covalently linked to a heterologous polypeptide, forming a chimeric  
25 polypeptide. In another embodiment, the chimeric polypeptide has G-protein coupled receptor activity.

In one aspect, the present invention provides an antibody that selectively binds to the receptor comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

30 In another aspect, the present invention provides an expression vector comprising a nucleic acid encoding a polypeptide comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

In another aspect, the present invention provides a host cell transfected with the expression vector.

In another aspect, the present invention provides a method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of: (i) contacting the compound with a polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor, the extracellular domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and (ii) determining the functional effect of the compound upon the extracellular domain.

In another aspect, the present invention provides a method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of: (i) contacting the compound with a polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and (ii) determining the functional effect of the compound upon the transmembrane domain.

In one embodiment, the polypeptide is a sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70% amino acid identity to a polypeptide encoding SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In another embodiment, polypeptide comprises an extracellular domain that is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide. In another embodiment, the polypeptide has G-protein coupled receptor activity. In another embodiment, the extracellular domain is linked to a solid phase, either covalently or non-covalently. In another embodiment, the functional effect is determined by measuring changes in intracellular cAMP, IP3, or  $\text{Ca}^{2+}$ . In another embodiment, the functional effect is a chemical effect. In another embodiment, the functional effect is a chemical effect. In another embodiment, the functional effect is determined by measuring binding of the compound to the extracellular domain. In another embodiment, the polypeptide is recombinant. In another embodiment, the polypeptide is expressed in a cell or cell membrane. In another embodiment, the cell is a eukaryotic cell.

In one embodiment, the polypeptide comprises an transmembrane domain that is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

In one aspect, the present invention provides a method of making a sensory transduction G-protein coupled receptor, the method comprising the step of

expressing the receptor from a recombinant expression vector comprising a nucleic acid encoding the receptor, wherein the amino acid sequence of the receptor comprises greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

5           In one aspect, the present invention provides a method of making a recombinant cell comprising a sensory transduction G-protein coupled receptor, the method comprising the step of transducing the cell with an expression vector comprising a nucleic acid encoding the receptor, wherein the amino acid sequence of the receptor comprises greater than about 70% amino acid identity to a polypeptide having a sequence  
10 of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

          In one aspect, the present invention provides a method of making an recombinant expression vector comprising a nucleic acid encoding a sensory transduction G-protein coupled receptor, the method comprising the step of ligating to an expression vector a nucleic acid encoding the receptor, wherein the amino acid sequence of the  
15 receptor comprises greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20           Figure 1 shows the proposed topology of GPCR-B3, with a large extracellular domain extending from amino acid 1 to about amino acid 580 of the rat GPCR-B3 amino acid sequence (corresponding to nucleotide residues 1-1740 of the rat sequence, with the ATG initiator methionine defined as residue 1), and seven  
25 transmembrane domains. The large extracellular domain may extend into the first transmembrane domain. Dark residues indicate identities between GPCR-B3 and GPCR-B4 (for a description of GPCR-B4, *see, e.g.*, USSN 60/095,464, filed July 28, 1998, and USSN 60/112,747, filed December 17, 1998; *see also* Hoon *et al.*, *Cell* 96:541-551 (1999)).

          Figure 2 is a western blot showing GPCR-B3 protein expression in taste  
30 buds but not in non-taste tissue. Using PCR assays, the following non-tongue tissues were screened for GPCR-B3 expression--brain, liver, olfactory epithelium, VNO, and heart. GPCR-B3 was expressed only in taste tissue (data not shown).

Figure 3 shows *in situ* hybridization of tongue tissue sections showing labeling of GPCR-B3 in taste receptor cells of taste buds, but not in adjacent non-taste tissue.

Figure 4 shows a chimeric receptor containing the entire extracellular domain of the murine mGluR1 receptor and the transmembrane domain comprising seven transmembrane regions and corresponding cytosolic loops, and C-terminal end from murine GPCR-B3.

Figure 5 shows HEK cells transfected with the chimeric glutamate/GPCR-B3 receptor described in Figure 4. Figure 5 shows calcium response to glutamate, demonstrating robust coupling of the chimeric receptor to phospholipase C. These results indicate that the chimeric glutamate/GPCR-B3 can couple to the promiscuous G protein  $G\alpha_{15}$  and trigger calcium responses that are detectable using the indicator Fura-2.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

The present invention provides for the first time nucleic acids encoding a taste cell specific G-protein coupled receptor. These nucleic acids and the receptors that they encode are referred to as "GPCR" for G-protein coupled receptor, and are designated as GPCR-B3. These taste cell specific GPCR are components of the taste transduction pathway. These nucleic acids provide valuable probes for the identification of taste cells, as the nucleic acids are specifically expressed in taste cells. For example, probes for GPCR polypeptides and proteins can be used to identify subsets of taste cells such as foliate cells and circumvallate cells, or specific taste receptor cells, e.g., sweet, sour, salty, and bitter. They also serve as tools for the generation of taste topographic maps that elucidate the relationship between the taste cells of the tongue and taste sensory neurons leading to taste centers in the brain. Furthermore, the nucleic acids and the proteins they encode can be used as probes to dissect taste-induced behaviors.

The invention also provides methods of screening for modulators, e.g., activators, inhibitors, stimulators, enhancers, agonists, and antagonists, of these novel taste cell GPCRs. Such modulators of taste transduction are useful for pharmacological and genetic modulation of taste signaling pathways. These methods of screening can be used to identify high affinity agonists and antagonists of taste cell activity. These modulatory compounds can then be used in the food and pharmaceutical industries to

customize taste. Thus, the invention provides assays for taste modulation, where GPCR-B3 acts as an direct or indirect reporter molecule for the effect of modulators on taste transduction. GPCRs can be used in assays, e.g., to measure changes in ion concentration, membrane potential, current flow, ion flux, transcription, signal  
5 transduction, receptor-ligand interactions, second messenger concentrations, *in vitro*, *in vivo*, and *ex vivo*. In one embodiment, GPCR-B3 can be used as an indirect reporter via attachment to a second reporter molecule such as green fluorescent protein (*see, e.g.*, Mistili & Spector, *Nature Biotechnology* 15:961-964 (1997)). In another embodiment, GPCR-B3 is recombinantly expressed in cells, and modulation of taste transduction via  
10 GPCR activity is assayed by measuring changes in  $Ca^{2+}$  levels.

Methods of assaying for modulators of taste transduction include *in vitro* ligand binding assays using GPCR-B3, portions thereof such as the extracellular domain, or chimeric proteins comprising one or more domains of GPCR-B3, oocyte GPCR-B3 expression; tissue culture cell GPCR-B3 expression; transcriptional activation of GPCR-B3; phosphorylation and dephosphorylation of GPCRs; G-protein binding to GPCRs;  
15 ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate; changes in intracellular calcium levels; and neurotransmitter release.

Finally, the invention provides for methods of detecting GPCR-B3 nucleic acid and protein expression, allowing investigation of taste transduction regulation and  
20 specific identification of taste receptor cells. GPCR-B3 also provides useful nucleic acid probes for paternity and forensic investigations. GPCR-B3 is a useful nucleic acid probe for identifying subpopulations of taste receptor cells such as foliate, fungiform, and circumvallate taste receptor cells. GPCR-B3 receptors can also be used to generate  
25 monoclonal and polyclonal antibodies useful for identifying taste receptor cells. Taste receptor cells can be identified using techniques such as reverse transcription and amplification of mRNA, isolation of total RNA or poly A<sup>+</sup> RNA, northern blotting, dot blotting, *in situ* hybridization, RNase protection, S1 digestion, probing DNA microchip arrays, western blots, and the like.

30 Functionally, GPCR-B3 represents a seven transmembrane G-protein coupled receptor involved in taste transduction, which interacts with a G-protein to mediate taste signal transduction (*see, e.g.*, Fong, *Cell Signal* 8:217 (1996); Baldwin, *Curr. Opin. Cell Biol.* 6:180 (1994)).

Structurally, the nucleotide sequence of GPCR-B3 (see, e.g., SEQ ID NOS:4-6, isolated from rat, mouse, and human respectively) encodes a polypeptide of approximately 840 amino acids with a predicted molecular weight of approximately 97 kDa and a predicted range of 92-102 kDa (see, e.g., SEQ ID NOS:1-3). Related GPCR-B3 genes from other species share at least about 70% amino acid identity over a amino acid region at least about 25 amino acids in length, optionally 50 to 100 amino acids in length. GPCR-B3 is specifically expressed in foliate and fungiform cells, with lower expression in circumvallate taste receptor cells of the tongue. GPCR-B3 is an moderately rare sequence found in approximately 1/150,000 cDNAs from an oligo-dT primed circumvallate cDNA library (see Example 1).

The present invention also provides polymorphic variants of the GPCR-B3 depicted in SEQ ID NO:1: variant #1, in which an isoleucine residue is substituted for a leucine acid residue at amino acid position 33; variant #2, in which an aspartic acid residue is substituted for a glutamic acid residue at amino acid position 84; and variant #3, in which a glycine residue is substituted for an alanine residue at amino acid position 90.

Specific regions of the GPCR-B3 nucleotide and amino acid sequence may be used to identify polymorphic variants, interspecies homologs, and alleles of GPCR-B3. This identification can be made *in vitro*, e.g., under stringent hybridization conditions or PCR (using primers encoding SEQ ID NOS:7-8) and sequencing, or by using the sequence information in a computer system for comparison with other nucleotide sequences. Typically, identification of polymorphic variants and alleles of GPCR-B3 is made by comparing an amino acid sequence of about 25 amino acids or more, e.g., 50-100 amino acids. Amino acid identity of approximately at least 70% or above, optionally 80%, optionally 90-95% or above typically demonstrates that a protein is a polymorphic variant, interspecies homolog, or allele of GPCR-B3. Sequence comparison can be performed using any of the sequence comparison algorithms discussed below. Antibodies that bind specifically to GPCR-B3 or a conserved region thereof can also be used to identify alleles, interspecies homologs, and polymorphic variants.

Polymorphic variants, interspecies homologs, and alleles of GPCR-B3 are confirmed by examining taste cell specific expression of the putative GPCR-B3 polypeptide. Typically, GPCR-B3 having the amino acid sequence of SEQ ID NO:1-3 is used as a positive control in comparison to the putative GPCR-B3 protein to demonstrate the identification of a polymorphic variant or allele of GPCR-B3. The polymorphic



variants, alleles and interspecies homologs are expected to retain the seven transmembrane structure of a G-protein coupled receptor.

GPCR-B3 nucleotide and amino acid sequence information may also be used to construct models of taste cell specific polypeptides in a computer system. These models are subsequently used to identify compounds that can activate or inhibit GPCR-B3. Such compounds that modulate the activity of GPCR B4 can be used to investigate the role of GPCR-B3 in taste transduction.

The isolation of GPCR-B3 for the first time provides a means for assaying for inhibitors and activators of G-protein coupled receptor taste transduction .

Biologically active GPCR-B3 is useful for testing inhibitors and activators of GPCR-B3 as taste transducers using *in vivo* and *in vitro* expression that measure, e.g., transcriptional activation of GPCR-B3; ligand binding; phosphorylation and dephosphorylation; binding to G-proteins; G-protein activation; regulatory molecule binding; voltage, membrane potential and conductance changes; ion flux; intracellular second messengers such as cAMP and inositol triphosphate; intracellular calcium levels; and neurotransmitter release. Such activators and inhibitors identified using GPCR-B3, can be used to further study taste transduction and to identify specific taste agonists and antagonists. Such activators and inhibitors are useful as pharmaceutical and food agents for customizing taste.

Methods of detecting GPCR-B3 nucleic acids and expression of GPCR-B3 are also useful for identifying taste cells and creating topological maps of the tongue and the relation of tongue taste receptor cells to taste sensory neurons in the brain. Chromosome localization of the genes encoding human GPCR-B3 can be used to identify diseases, mutations, and traits caused by and associated with GPCR-B3.

## II. Definitions

As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

"Taste receptor cells" are neuroepithelial cells that are organized into groups to form taste buds of the tongue, e.g., foliate, fungiform, and circumvallate cells (see, e.g., Roper *et al.*, *Ann. Rev. Neurosci.* 12:329-353 (1989)).

"GPCR-B3," also called "TR1," refers to a G-protein coupled receptor is specifically expressed in taste receptor cells such as foliate, fungiform, and circumvallate cells (see, e.g., Hoon *et al.*, *Cell* 96:541-551 (1999), herein incorporated by reference in

its entirety). Such taste cells can be identified because they express specific molecules such as Gustducin, a taste cell specific G protein (McLaughlin *et al.*, *Nature* 357:563-569 (1992)). Taste receptor cells can also be identified on the basis of morphology (*see, e.g., Roper, supra*).

5                   GPCR-B3 encodes GPCRs with seven transmembrane regions that have "G-protein coupled receptor activity," e.g., they bind to G-proteins in response to extracellular stimuli and promote production of second messengers such as IP3, cAMP, and Ca<sup>2+</sup> via stimulation of enzymes such as phospholipase C and adenylate cyclase (for a description of the structure and function of GPCRs, *see, e.g., Fong, supra, and Baldwin,*  
10 *supra*).

The term GPCR-B3 therefore refers to polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have about 70% amino acid sequence identity, optionally about 75, 80, 85, 90, or 95% amino acid sequence identity to SEQ ID NOS:1-3 over a window of about 25 amino acids, optionally 50-100 amino acids; (2) bind  
15 to antibodies raised against an immunogen comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-3 and conservatively modified variants thereof; (3) specifically hybridize (with a size of at least about 500, optionally at least about 900 nucleotides) under stringent hybridization conditions to a sequence selected from the group consisting of SEQ ID NO:4-6, and conservatively modified variants  
20 thereof; or (4) are amplified by primers that specifically hybridize under stringent hybridization conditions to the same sequence as a degenerate primer sets encoding SEQ ID NOS:7-8.

Topologically, sensory GPCRs have an N-terminal "extracellular domain," a "transmembrane domain" comprising seven transmembrane regions and corresponding  
25 cytoplasmic and extracellular loops, and a C-terminal "cytoplasmic domain" (*see Figure 1; see also Hoon et al., Cell* 96:541-551 (1999); Buck & Axel, *Cell* 65:175-187 (1991)). These domains can be structurally identified using methods known to those of skill in the art, such as sequence analysis programs that identify hydrophobic and hydrophilic domains (*see, e.g., Kyte & Doolittle, J. Mol. Biol.* 157:105-132 (1982)). Such domains  
30 are useful for making chimeric proteins and for *in vitro* assays of the invention.

"Extracellular domain" therefore refers to the domain of GPCR-B3 that protrudes from the cellular membrane and binds to extracellular ligand. This region starts at the N-terminus and ends approximately at the conserved glutamic acid at amino acid position 563 plus or minus approximately 20 amino acids. The region corresponding to

amino acids 1-580 of SEQ ID NO:1 (nucleotides 1-1740, with nucleotide 1 starting at the ATG initiator methionine codon; *see also* Figure 1) is one embodiment of an extracellular domain that extends slightly into the transmembrane domain. This embodiment is useful for *in vitro* ligand binding assays, both soluble and solid phase.

5                   “Transmembrane domain,” comprising seven transmembrane regions plus the corresponding cytoplasmic and extracellular loops, refers to the domain of GPCR-B3 that starts approximately at the conserved glutamic acid residue at amino acid position 563 plus or minus approximately 20 amino acids and ends approximately at the conserved tyrosine amino acid residue at position 812 plus or minus approximately 10 amino acids.

10                   “Cytoplasmic domain” refers to the domain of GPCR-B3 that starts at the conserved tyrosine amino acid residue at position 812 plus or minus approximately 10 amino acids and continues to the C-terminus of the polypeptide.

                  “Biological sample” as used herein is a sample of biological tissue or fluid that contains GPCR-B3 or nucleic acid encoding GPCR-B3 protein. Such samples  
15 include, but are not limited to, tissue isolated from humans, mice, and rats, in particular, ton. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. A biological sample is typically obtained from a eukaryotic organism, such as insects, protozoa, birds, fish, reptiles, and preferably a mammal such as rat, mouse, cow, dog, guinea pig, or rabbit, and most preferably a primate such as  
20 chimpanzees or humans. Tissues include tongue tissue, isolated taste buds, and testis tissue.

                  “GPCR activity” refers to the ability of a GPCR to transduce a signal. Such activity can be measured in a heterologous cell, by coupling a GPCR (or a chimeric GPCR) to either a G-protein or promiscuous G-protein such as G $\alpha$ 15, and an enzyme  
25 such as PLC, and measuring increases in intracellular calcium using (Offermans & Simon, *J. Biol. Chem.* 270:15175-15180 (1995)). Receptor activity can be effectively measured by recording ligand-induced changes in [Ca<sup>2+</sup>]<sub>i</sub> using fluorescent Ca<sup>2+</sup>-indicator dyes and fluorometric imaging. Optionally, the polypeptides of the invention are involved in sensory transduction, optionally taste transduction in taste cells.

30                   The phrase “functional effects” in the context of assays for testing compounds that modulate GPCR-B3 mediated taste transduction includes the determination of any parameter that is indirectly or directly under the influence of the receptor, e.g., functional, physical and chemical effects. It includes ligand binding,

changes in ion flux, membrane potential, current flow, transcription, G-protein binding, GPCR phosphorylation or dephosphorylation, signal transduction, receptor-ligand interactions, second messenger concentrations (e.g., cAMP, IP3, or intracellular  $\text{Ca}^{2+}$ ), *in vitro*, *in vivo*, and *ex vivo* and also includes other physiologic effects such increases or  
5 decreases of neurotransmitter or hormone release.

By "determining the functional effect" is meant assays for a compound that increases or decreases a parameter that is indirectly or directly under the influence of GPCR-B3, e.g., functional, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic  
10 characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties, patch clamping, voltage-sensitive dyes, whole cell currents, radioisotope efflux, inducible markers, oocyte GPCR-B3 expression; tissue culture cell GPCR-B3 expression; transcriptional activation of GPCR-B3; ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays;  
15 changes in intracellular second messengers such as cAMP and inositol triphosphate (IP3); changes in intracellular calcium levels; neurotransmitter release, and the like.

"Inhibitors," "activators," and "modulators" of GPCR-B3 are used interchangeably to refer to inhibitory, activating, or modulating molecules identified using *in vitro* and *in vivo* assays for taste transduction, e.g., ligands, agonists, antagonists,  
20 and their homologs and mimetics. Inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate taste transduction, e.g., antagonists. Activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize or up regulate taste transduction, e.g., agonists. Modulators include compounds that, e.g., alter  
25 the interaction of a receptor with: extracellular proteins that bind activators or inhibitor (e.g., ebnerin and other members of the hydrophobic carrier family); G-proteins; kinases (e.g., homologs of rhodopsin kinase and beta adrenergic receptor kinases that are involved in deactivation and desensitization of a receptor); and arrestin-like proteins, which also deactivate and desensitize receptors. Modulators include genetically modified  
30 versions of GPCR-B3, e.g., with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing GPCR-B3 in cells or cell membranes, applying putative modulator compounds, and then determining the functional effects on taste transduction, as described above. Samples or assays comprising GPCR-

B3 that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative GPCR-B3 activity value of 100%. Inhibition of GPCR-B3 is achieved when the GPCR-B3 activity value relative to the control is about 80%, optionally 50%, 25-0%. Activation of GPCR-B3 is achieved when the GPCR-B3 activity value relative to the control is 110%, optionally 150%, 200-500%, 1000-3000% higher.

"Biologically active" GPCR-B3 refers to GPCR-B3 having GPCR activity as described above, involved in taste transduction in taste receptor cells.

The terms "isolated" "purified" or "biologically pure" refer to material that is substantially or essentially free from components which normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. In particular, an isolated GPCR-B3 nucleic acid is separated from open reading frames that flank the GPCR-B3 gene and encode proteins other than GPCR-B3. The term "purified" denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, optionally at least 95% pure, and optionally at least 99% pure.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991);

Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide.

Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine; and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
  - 2) Aspartic acid (D), Glutamic acid (E);
  - 3) Asparagine (N), Glutamine (Q);
  - 4) Arginine (R), Lysine (K);
  - 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
  - 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
  - 7) Serine (S), Threonine (T); and
  - 8) Cysteine (C), Methionine (M)
- (see, e.g., Creighton, *Proteins* (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts *et al.*, *Molecular Biology of the Cell* (3<sup>rd</sup> ed., 1994) and Cantor and Schimmel, *Biophysical Chemistry Part I: The Conformation of Biological Macromolecules* (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains.

Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 50 to 350 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of  $\beta$ -sheet and  $\alpha$ -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include  $^{32}\text{P}$ , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins for which ant or 7 can be made detectable, e.g., by incorporating a radiolabel into the peptide, and used to detect antibodies specifically reactive with the peptide).

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are optionally directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has



been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise  
5 abnormally expressed, under expressed or not expressed at all.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes  
10 arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that  
15 direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that  
20 is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence  
25 directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector  
30 includes a nucleic acid to be transcribed operably linked to a promoter.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 70% identity, optionally 75%, 80%, 85%, 90%, or 95% identity over a

specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the  
5 compliment of a test sequence. Optionally, the identity exists over a region that is at least about 50 amino acids or nucleotides in length, or more preferably over a region that is 75-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison  
10 algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program  
15 parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of  
20 contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by  
25 computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

30 One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol.*

*Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al.*, *Nuc. Acids Res.* 12:387-395 (1984).

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1997) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990), respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either

sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5; N=4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at

higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or

lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce  $F(ab)'_2$ , a dimer of Fab which itself is a light chain joined to  $V_H$ - $C_H1$  by a disulfide bond. The  $F(ab)'_2$  may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the  $F(ab)'_2$  dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (*see Fundamental Immunology* (Paul ed., 3d ed. 1993)). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990)).

For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (*see, e.g., Kohler & Milstein, Nature* 256:495-497 (1975); Kozbor *et al., Immunology Today* 4: 72 (1983); Cole *et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy* (1985)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990); Marks *et al., Biotechnology* 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding

site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable  
5 region having a different or altered antigen specificity.

An "anti-GPCR-B3" antibody is an antibody or antibody fragment that specifically binds a polypeptide encoded by the GPCR-B3 gene, cDNA, or a subsequence thereof.

The term "immunoassay" is an assay that uses an antibody to specifically  
10 bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in  
15 a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For  
20 example, polyclonal antibodies raised to GPCR-B3 from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with GPCR-B3 and not with other proteins, except for polymorphic variants and alleles of GPCR-B3. This selection may be achieved by subtracting out antibodies that cross-react with GPCR-B3 molecules from other species.

A variety of immunoassay formats may be used to select antibodies specifically  
25 immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (*see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual* (1988), for a description of immunoassay formats and conditions that can be used to determine specific  
30 immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

The phrase "selectively associates with" refers to the ability of a nucleic acid to "selectively hybridize" with another as defined above, or the ability of an antibody to "selectively (or specifically) bind to a protein, as defined above.

By "host cell" is meant a cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa and the like, e.g., cultured cells, explants, and cells  
5 *in vivo*.

### III. Isolation of the nucleic acid encoding GPCR-B3

#### A. General recombinant DNA methods

This invention relies on routine techniques in the field of recombinant  
10 genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

For nucleic acids, sizes are given in either kilobases (kb) or base pairs  
15 (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or amino acid residue numbers. Proteins sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.

20 Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, *Tetrahedron Letts.* 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter *et. al.*, *Nucleic Acids Res.* 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis  
25 or by anion-exchange HPLC as described in Pearson & Reanier, *J. Chrom.* 255:137-149 (1983).

The sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace *et al.*, *Gene* 16:21-26 (1981).

30

#### B. Cloning methods for the isolation of nucleotide sequences encoding GPCR-B3

In general, the nucleic acid sequences encoding GPCR-B3 and related nucleic acid sequence homologs are cloned from cDNA and genomic DNA libraries by



hybridization with a probe, or isolated using amplification techniques with oligonucleotide primers. For example, GPCR-B3 sequences are typically isolated from mammalian nucleic acid (genomic or cDNA) libraries by hybridizing with a nucleic acid probe, the sequence of which can be derived from SEQ ID NOS:4-6. A suitable tissue  
5 from which GPCR-B3 RNA and cDNA can be isolated is tongue tissue, optionally taste bud tissue or individual taste cells.

Amplification techniques using primers can also be used to amplify and isolate GPCR-B3 from DNA or RNA. The degenerate primers encoding the following amino acid sequences can also be used to amplify a sequence of GPCR-B3: SEQ ID  
10 NOS:7-8 (*see, e.g., Dieffenbach & Dveksler, PCR Primer: A Laboratory Manual (1995)*). These primers can be used, e.g., to amplify either the full length sequence or a probe of one to several hundred nucleotides, which is then used to screen a mammalian library for full-length GPCR-B3.

Nucleic acids encoding GPCR-B3 can also be isolated from expression  
15 libraries using antibodies as probes. Such polyclonal or monoclonal antibodies can be raised using the sequence of SEQ ID NOS:1-3.

GPCR-B3 polymorphic variants, alleles, and interspecies homologs that are substantially identical to GPCR-B3 can be isolated using GPCR-B3 nucleic acid probes, and oligonucleotides under stringent hybridization conditions, by screening  
20 libraries. Alternatively, expression libraries can be used to clone GPCR-B3 and GPCR-B3 polymorphic variants, alleles, and interspecies homologs, by detecting expressed homologs immunologically with antisera or purified antibodies made against GPCR-B3, which also recognize and selectively bind to the GPCR-B3 homolog.

To make a cDNA library, one should choose a source that is rich in  
25 GPCR-B3 mRNA, e.g., tongue tissue, or isolated taste buds. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening and cloning. Methods for making and screening cDNA libraries are well known (*see, e.g., Gubler & Hoffman, Gene 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra*).

30 For a genomic library, the DNA is extracted from the tissue and either mechanically sheared or enzymatically digested to yield fragments of about 12-20 kb. The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged *in vitro*. Recombinant phage are analyzed by plaque hybridization as described in Benton &

Davis, *Science* 196:180-182 (1977). Colony hybridization is carried out as generally described in Grunstein *et al.*, *Proc. Natl. Acad. Sci. USA.*, 72:3961-3965 (1975).

An alternative method of isolating GPCR-B3 nucleic acid and its homologs combines the use of synthetic oligonucleotide primers and amplification of an RNA or DNA template (see U.S. Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis *et al.*, eds, 1990)). Methods such as polymerase chain reaction (PCR) and ligase chain reaction (LCR) can be used to amplify nucleic acid sequences of GPCR-B3 directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Degenerate oligonucleotides can be designed to amplify GPCR-B3 homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. Polymerase chain reaction or other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of GPCR-B3 encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Gene expression of GPCR-B3 can also be analyzed by techniques known in the art, e.g., reverse transcription and amplification of mRNA, isolation of total RNA or poly A<sup>+</sup> RNA, northern blotting, dot blotting, *in situ* hybridization, RNase protection, probing DNA microchip arrays, and the like. In one embodiment, high density oligonucleotide analysis technology (e.g., GeneChip™) is used to identify homologs and polymorphic variants of the GPCRs of the invention. In the case where the homologs being identified are linked to a known disease, they can be used with GeneChip™ as a diagnostic tool in detecting the disease in a biological sample, see, e.g., Gunthand *et al.*, *AIDS Res. Hum. Retroviruses* 14: 869-876 (1998); Kozal *et al.*, *Nat. Med.* 2:753-759 (1996); Matson *et al.*, *Anal. Biochem.* 224:110-106 (1995); Lockhart *et al.*, *Nat. Biotechnol.* 14:1675-1680 (1996); Gingeras *et al.*, *Genome Res.* 8:435-448 (1998); Hacia *et al.*, *Nucleic Acids Res.* 26:3865-3866 (1998).

Synthetic oligonucleotides can be used to construct recombinant GPCR-B3 genes for use as probes or for expression of protein. This method is performed using a series of overlapping oligonucleotides usually 40-120 bp in length, representing both the sense and non-sense strands of the gene. These DNA fragments are then annealed, ligated and cloned. Alternatively, amplification techniques can be used with precise

primers to amplify a specific subsequence of the GPCR-B3 nucleic acid. The specific subsequence is then ligated into an expression vector.

The nucleic acid encoding GPCR-B3 is typically cloned into intermediate vectors before transformation into prokaryotic or eukaryotic cells for replication and/or  
5 expression. These intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors.

Optionally, nucleic acids encoding chimeric proteins comprising GPCR-B3 or domains thereof can be made according to standard techniques. For example, a domain such as ligand binding domain, an extracellular domain, a transmembrane domain  
10 (e.g., one comprising seven transmembrane regions and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc., can be covalently linked to a heterologous protein. For example, an extracellular domain can be linked to a heterologous GPCR transmembrane domain, or a heterologous GPCR extracellular domain can be linked to a transmembrane domain.  
15 Other heterologous proteins of choice include, e.g., green fluorescent protein,  $\beta$ -gal, glutamate receptor, and the rhodopsin presequence.

### *C. Expression in prokaryotes and eukaryotes*

To obtain high level expression of a cloned gene or nucleic acid, such as  
20 those cDNAs encoding GPCR-B3, one typically subclones GPCR-B3 into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for  
25 expressing the GPCR-B3 protein are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. In one embodiment, the eukaryotic expression  
30 vector is an adenoviral vector, an adeno-associated vector, or a retroviral vector.

The promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is optionally positioned about the same distance from the heterologous transcription start site as it is from the transcription

start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the GPCR-B3 encoding nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding GPCR-B3 and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. The nucleic acid sequence encoding GPCR-B3 may typically be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Such signal peptides would include, among others, the signal peptides from tissue plasminogen activator, insulin, and neuron growth factor, and juvenile hormone esterase of *Heliothis virescens*. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as GST and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc.

Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A<sup>+</sup>, pMTO10/A<sup>+</sup>, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Some expression systems have markers that provide gene amplification such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase.

Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a GPCR-B3 encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

5                   The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance  
10 genes known in the art are suitable. The prokaryotic sequences are typically chosen such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of GPCR-B3 protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-  
15 17622 (1989); *Guide to Protein Purification, in Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).

20                   Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host  
25 cell (*see, e.g., Sambrook et al., supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing GPCR-B3.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of GPCR-B3, which is recovered from  
30 the culture using standard techniques identified below.

#### IV. Purification of GPCR-B3

Either naturally occurring or recombinant GPCR-B3 can be purified for use in functional assays. Optionally, recombinant GPCR-B3 is purified. Naturally

occurring GPCR-B3 is purified, e.g., from mammalian tissue such as tongue tissue, and any other source of a GPCR-B3 homolog. Recombinant GPCR-B3 is purified from any suitable expression system, e.g., bacterial and eukaryotic expression systems, e.g., CHO cells or insect cells.

5 GPCR-B3 may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (*see, e.g., Scopes, Protein Purification: Principles and Practice* (1982); U.S. Patent No. 4,673,641; Ausubel *et al., supra*; and Sambrook *et al., supra*).

10 A number of procedures can be employed when recombinant GPCR-B3 is being purified. For example, proteins having established molecular adhesion properties can be reversibly fused to GPCR-B3. With the appropriate ligand, GPCR-B3 can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally  
15 GPCR-B3 could be purified using immunoaffinity columns.

#### *A. Purification of GPCR-B3 from recombinant cells*

Recombinant proteins are expressed by transformed bacteria or eukaryotic cells such as CHO or insect cells in large amounts, typically after promoter induction; but  
20 expression can be constitutive. Promoter induction with IPTG is a one example of an inducible promoter system. Cells are grown according to standard procedures in the art. Fresh or frozen cells are used for isolation of protein.

Proteins expressed in bacteria may form insoluble aggregates ("inclusion bodies"). Several protocols are suitable for purification of GPCR-B3 inclusion bodies.  
25 For example, purification of inclusion bodies typically involves the extraction, separation and/or purification of inclusion bodies by disruption of bacterial cells, e.g., by incubation in a buffer of 50 mM TRIS/HCL pH 7.5, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 0.1 mM ATP, and 1 mM PMSF. The cell suspension can be lysed using 2-3 passages through a French Press, homogenized using a Polytron (Brinkman Instruments) or  
30 sonicated on ice. Alternate methods of lysing bacteria are apparent to those of skill in the art (*see, e.g., Sambrook et al., supra*; Ausubel *et al., supra*).

If necessary, the inclusion bodies are solubilized, and the lysed cell suspension is typically centrifuged to remove unwanted insoluble matter. Proteins that formed the inclusion bodies may be renatured by dilution or dialysis with a compatible

buffer. Suitable solvents include, but are not limited to urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Some solvents which are capable of solubilizing aggregate-forming proteins, for example SDS (sodium dodecyl sulfate), 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity. Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein. Other suitable buffers are known to those skilled in the art. GPCR-B3 is separated from other bacterial proteins by standard separation techniques, e.g., with Ni-NTA agarose resin.

Alternatively, it is possible to purify GPCR-B3 from bacteria periplasm. After lysis of the bacteria, when GPCR-B3 is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to skill in the art. To isolate recombinant proteins from the periplasm, the bacterial cells are centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO<sub>4</sub> and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.

#### *B. Standard protein separation techniques for purifying GPCR-B3*

##### Solubility fractionation

Often as an initial step, particularly if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. In one embodiment, the salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most

hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other  
5 methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

#### Size differential filtration

The molecular weight of GPCR-B3 can be used to isolated it from proteins  
10 of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the  
15 molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

#### Column chromatography

GPCR-B3 can also be separated from other proteins on the basis of its size,  
20 net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from  
25 many different manufacturers (e.g., Pharmacia Biotech).

### **V. Immunological detection of GPCR-B3**

In addition to the detection of GPCR-B3 genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect GPCR-  
30 B3, e.g., to identify taste receptor cells and variants of GPCR-B3. Immunoassays can be used to qualitatively or quantitatively analyze GPCR-B3. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).



### A. Antibodies to GPCR-B3

Methods of producing polyclonal and monoclonal antibodies that react specifically with GPCR-B3 are known to those of skill in the art (*see, e.g., Coligan, Current Protocols in Immunology* (1991); Harlow & Lane, *supra*; Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986); and Kohler & Milstein, *Nature* 256:495-497 (1975)). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (*see, e.g., Huse et al., Science* 246:1275-1281 (1989); Ward *et al., Nature* 341:544-546 (1989)).

A number of GPCR-B3 comprising immunogens may be used to produce antibodies specifically reactive with GPCR-B3. For example, recombinant GPCR-B3 or an antigenic fragment thereof, is isolated as described herein. Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is one embodiment of an immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Naturally occurring protein may also be used either in pure or impure form. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in the art. An inbred strain of mice (*e.g., BALB/C mice*) or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to GPCR-B3. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (*see Harlow & Lane, supra*).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*see Kohler & Milstein, Eur. J. Immunol.* 6:511-519 (1976)). Alternative methods of immortalization

include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced  
5 by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science* 246:1275-1281 (1989).

Monoclonal antibodies and polyclonal sera are collected and titrated  
10 against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Typically, polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity against non-GPCR-B3 proteins or even other related proteins from other organisms, using a competitive binding immunoassay. Specific polyclonal antisera and monoclonal  
15 antibodies will usually bind with a  $K_d$  of at least about 0.1 mM, more usually at least about 1  $\mu$ M, optionally at least about 0.1  $\mu$ M or better, and optionally 0.01  $\mu$ M or better.

Once GPCR-B3 specific antibodies are available, GPCR-B3 can be detected by a variety of immunoassay methods. For a review of immunological and immunoassay procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed.  
20 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

#### *B. Immunological binding assays*

GPCR-B3 can be detected and/or quantified using any of a number of well  
25 recognized immunological binding assays (*see, e.g.*, U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed. 1991). Immunological binding assays  
30 (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case the GPCR-B3 or antigenic subsequence thereof). The antibody (e.g., anti-GPCR-B3) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent may be a labeled GPCR-B3 polypeptide or a labeled anti-GPCR-B3 antibody.

- 5 Alternatively, the labeling agent may be a third moiety, such as a secondary antibody, that specifically binds to the antibody/GPCR-B3 complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-
- 10 immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, e.g., Kronval *et al.*, *J. Immunol.* 111:1401-1406 (1973); Akerstrom *et al.*, *J. Immunol.* 135:2589-2542 (1985)). The labeling agent can be modified with a detectable moiety, such as biotin, to which another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.
- 15 Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient
- 20 temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

#### Non-competitive assay formats

- Immunoassays for detecting GPCR-B3 in samples may be either
- 25 competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of antigen is directly measured. In one embodiment "sandwich" assay, for example, the anti-GPCR-B3 antibodies can be bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture GPCR-B3 present in the test sample. GPCR-B3 is thus immobilized is then bound by a labeling
- 30 agent, such as a second GPCR-B3 antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to

which another molecule specifically binds, e.g., streptavidin, to provide a detectable moiety.

#### Competitive assay formats

5                   In competitive assays, the amount of GPCR-B3 present in the sample is measured indirectly by measuring the amount of a known, added (exogenous) GPCR-B3 displaced (competed away) from an anti-GPCR-B3 antibody by the unknown GPCR-B3 present in a sample. In one competitive assay, a known amount of GPCR-B3 is added to a sample and the sample is then contacted with an antibody that specifically binds to  
10 GPCR-B3. The amount of exogenous GPCR-B3 bound to the antibody is inversely proportional to the concentration of GPCR-B3 present in the sample. In one embodiment, the antibody is immobilized on a solid substrate. The amount of GPCR-B3 bound to the antibody may be determined either by measuring the amount of GPCR-B3 present in a GPCR-B3/antibody complex, or alternatively by measuring the amount of remaining  
15 uncomplexed protein. The amount of GPCR-B3 may be detected by providing a labeled GPCR-B3 molecule.

A hapten inhibition assay is another competitive assay. In this assay the known GPCR-B3, is immobilized on a solid substrate. A known amount of anti-GPCR-B3 antibody is added to the sample, and the sample is then contacted with the  
20 immobilized GPCR-B3. The amount of anti-GPCR-B3 antibody bound to the known immobilized GPCR-B3 is inversely proportional to the amount of GPCR-B3 present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the  
25 subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

#### Cross-reactivity determinations

Immunoassays in the competitive binding format can also be used for  
30 crossreactivity determinations. For example, a protein at least partially encoded by SEQ ID NOS:1-3 can be immobilized to a solid support. Proteins (e.g., GPCR-B3 proteins and homologs) are added to the assay that compete for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of GPCR-B3 encoded by

SEQ ID NO:1-3 to compete with itself. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by

5 immunoabsorption with the added considered proteins, e.g., distantly related homologs.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele or polymorphic variant of GPCR-B3, to the immunogen protein (i.e., GPCR-B3 of SEQ ID NOS:1-3). In order to make this comparison, the two proteins are  
10 each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the protein encoded by SEQ ID NOS:1-3 that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies  
15 generated to a GPCR-B3 immunogen.

#### Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of GPCR-B3 in the sample. The technique generally comprises separating  
20 sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind GPCR-B3. The anti-GPCR-B3 antibodies specifically bind to the GPCR-B3 on the solid support. These antibodies may be directly labeled or alternatively may be  
25 subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-GPCR-B3 antibodies.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard  
30 techniques (*see Monroe et al., Amer. Clin. Prod. Rev. 5:34-41 (1986)*).

#### Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen

or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as  
5 bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used.

### Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific  
10 binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical,  
15 optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., DYNABEADS<sup>TM</sup>), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g.,  
20 polystyrene, polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation,  
25 and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to another molecules (e.g., streptavidin) molecule, which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent  
30 compound, or a chemiluminescent compound. The ligands and their targets can be used in any suitable combination with antibodies that recognize GPCR-B3, or secondary antibodies that recognize anti-GPCR-B3.

The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as

labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc:

Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, e.g.,  
5 luminol. For a review of various labeling or signal producing systems that may be used, see U.S. Patent No. 4,391,904.

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a  
10 fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and  
15 detecting the resulting reaction product. Finally simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For  
20 instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

## 25 VI. Assays for modulators of GPCR-B3

### *A. Assays for GPCR-B3 activity*

GPCR-B3 and its alleles and polymorphic variants are G-protein coupled receptors that participate in taste transduction. The activity of GPCR-B3 polypeptides can be assessed using a variety of *in vitro* and *in vivo* assays that determine functional,  
30 physical and chemical effects, e.g., measuring ligand binding (e.g., by radioactive ligand binding), second messengers (e.g., cAMP, cGMP, IP<sub>3</sub>, DAG, or Ca<sup>2+</sup>), ion flux, phosphorylation levels, transcription levels, neurotransmitter levels, and the like. Furthermore, such assays can be used to test for inhibitors and activators of GPCR-B3.

Modulators can also be genetically altered versions of GPCR-B3. Such modulators of taste transduction activity are useful for customizing taste.

The GPCR-B3 of the assay will be selected from a polypeptide having a sequence of SEQ ID NOS:1-3 or conservatively modified variant thereof. Alternatively, the GPCR-B3 of the assay will be derived from a eukaryote and include an amino acid subsequence having amino acid sequence identity SEQ ID NOS:1-3. Generally, the amino acid sequence identity will be at least 70%, optionally at least 85%, most optionally at least 90-95%. Optionally, the polypeptide of the assays will comprise a domain of GPCR-B3, such as an extracellular domain, transmembrane domain, cytoplasmic domain, ligand binding domain, subunit association domain, active site, and the like. Either GPCR-B3 or a domain thereof can be covalently linked to a heterologous protein to create a chimeric protein used in the assays described herein.

Modulators of GPCR-B3 activity are tested using GPCR-B3 polypeptides as described above, either recombinant or naturally occurring. The protein can be isolated, expressed in a cell, expressed in a membrane derived from a cell, expressed in tissue or in an animal, either recombinant or naturally occurring. For example, tongue slices, dissociated cells from a tongue, transformed cells, or membranes can be used. Modulation is tested using one of the *in vitro* or *in vivo* assays described herein. Taste transduction can also be examined *in vitro* with soluble or solid state reactions, using a chimeric molecule such as an extracellular domain of a receptor covalently linked to a heterologous signal transduction domain, or a heterologous extracellular domain covalently linked to the transmembrane and or cytoplasmic domain of a receptor. Furthermore, ligand-binding domains of the protein of interest can be used in vitro in soluble or solid state reactions to assay for ligand binding.

Ligand binding to GPCR-B3, a domain, or chimeric protein can be tested in solution, in a bilayer membrane, attached to a solid phase, in a lipid monolayer, or in vesicles. Binding of a modulator can be tested using, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index) hydrodynamic (e.g., shape), chromatographic, or solubility properties.

Receptor-G-protein interactions can also be examined. For example, binding of the G-protein to the receptor or its release from the receptor can be examined. For example, in the absence of GTP, an activator will lead to the formation of a tight complex of a G protein (all three subunits) with the receptor. This complex can be detected in a variety of ways, as noted above. Such an assay can be modified to search



for inhibitors. Add an activator to the receptor and G protein in the absence of GTP, form a tight complex, and then screen for inhibitors by looking at dissociation of the receptor-G protein complex. In the presence of GTP, release of the alpha subunit of the G protein from the other two G protein subunits serves as a criterion of activation.

5           An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G proteins, and modulation of diverse channels by Gi and other G proteins. Downstream  
10 consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

          Activated GPCR receptors become substrates for kinases that phosphorylate the C-terminal tail of the receptor (and possibly other sites as well). Thus, activators will promote the transfer of  $^{32}\text{P}$  from gamma-labeled GTP to the receptor,  
15 which can be assayed with a scintillation counter. The phosphorylation of the C-terminal tail will promote the binding of arrestin-like proteins and will interfere with the binding of G-proteins. The kinase/arrestin pathway plays a key role in the desensitization of many GPCR receptors. For example, compounds that modulate the duration a taste receptor stays active would be useful as a means of prolonging a desired taste or cutting off an  
20 unpleasant one. For a general review of GPCR signal transduction and methods of assaying signal transduction, see, e.g., *Methods in Enzymology*, vols. 237 and 238 (1994) and volume 96 (1983); Bourne *et al.*, *Nature* 10:349:117-27 (1991); Bourne *et al.*, *Nature* 348:125-32 (1990); Pitcher *et al.*, *Annu. Rev. Biochem.* 67:653-92 (1998).

          Samples or assays that are treated with a potential GPCR-B3 inhibitor or  
25 activator are compared to control samples without the test compound, to examine the extent of modulation. Control samples (untreated with activators or inhibitors) are assigned a relative GPCR-B3 activity value of 100. Inhibition of GPCR-B3 is achieved when the GPCR-B3 activity value relative to the control is about 90%, optionally 50%, optionally 25-0%. Activation of GPCR-B3 is achieved when the GPCR-B3 activity value  
30 relative to the control is 110%, optionally 150%, 200-500%, or 1000-2000%.

          Changes in ion flux may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing GPCR-B3. One means to determine changes in cellular polarization is by measuring changes in current (thereby measuring changes in polarization) with voltage-clamp and patch-clamp

techniques, e.g., the "cell-attached" mode, the "inside-out" mode, and the "whole cell" mode (see, e.g., Ackerman *et al.*, *New Engl. J. Med.* 336:1575-1595 (1997)). Whole cell currents are conveniently determined using the standard methodology (see, e.g., Hamil *et al.*, *Pflugers. Archiv.* 391:85 (1981)). Other known assays include: radiolabeled ion flux assays and fluorescence assays using voltage-sensitive dyes (see, e.g., Vestergaard-Bogind *et al.*, *J. Membrane Biol.* 88:67-75 (1988); Gonzales & Tsien, *Chem. Biol.* 4:269-277 (1997); Daniel *et al.*, *J. Pharmacol. Meth.* 25:185-193 (1991); Holevinsky *et al.*, *J. Membrane Biology* 137:59-70 (1994)). Generally, the compounds to be tested are present in the range from 1 pM to 100 mM.

10           The effects of the test compounds upon the function of the polypeptides can be measured by examining any of the parameters described above. Any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects  
15   such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as  $\text{Ca}^{2+}$ , IP3 or cAMP.

          Assays for G-protein coupled receptors include cells that are loaded with  
20   ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other G-protein coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (e.g., agonists, antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion -  
25   sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. For G-protein coupled receptors, promiscuous G-proteins such as  $\text{G}\alpha 15$  and  $\text{G}\alpha 16$  can be used in the assay of choice (Wilkie *et al.*, *Proc. Nat'l Acad. Sci. USA* 88:10049-10053 (1991)). Such promiscuous G-proteins allow  
30   coupling of a wide range of receptors.

          Receptor activation typically initiates subsequent intracellular events, e.g., increases in second messengers such as IP3, which releases intracellular stores of calcium ions. Activation of some G-protein coupled receptors stimulates the formation of inositol

triphosphate (IP3) through phospholipase C-mediated hydrolysis of phosphatidylinositol (Berridge & Irvine, *Nature* 312:315-21 (1984)). IP3 in turn stimulates the release of intracellular calcium ion stores. Thus, a change in cytoplasmic calcium ion levels, or a change in second messenger levels such as IP3 can be used to assess G-protein coupled receptor function. Cells expressing such G-protein coupled receptors may exhibit increased cytoplasmic calcium levels as a result of contribution from both intracellular stores and via activation of ion channels, in which case it may be desirable although not necessary to conduct such assays in calcium-free buffer, optionally supplemented with a chelating agent such as EGTA, to distinguish fluorescence response resulting from calcium release from internal stores.

Other assays can involve determining the activity of receptors which, when activated, result in a change in the level of intracellular cyclic nucleotides, e.g., cAMP or cGMP, by activating or inhibiting enzymes such as adenylate cyclase. There are cyclic nucleotide-gated ion channels, e.g., rod photoreceptor cell channels and olfactory neuron channels that are permeable to cations upon activation by binding of cAMP or cGMP (*see, e.g., Altenhofen et al., Proc. Natl. Acad. Sci. U.S.A.* 88:9868-9872 (1991) and Dhallan *et al., Nature* 347:184-187 (1990)). In cases where activation of the receptor results in a decrease in cyclic nucleotide levels, it may be preferable to expose the cells to agents that increase intracellular cyclic nucleotide levels, e.g., forskolin, prior to adding a receptor-activating compound to the cells in the assay. Cells for this type of assay can be made by co-transfection of a host cell with DNA encoding a cyclic nucleotide-gated ion channel, GPCR phosphatase and DNA encoding a receptor (e.g., certain glutamate receptors, muscarinic acetylcholine receptors, dopamine receptors, serotonin receptors, and the like), which, when activated, causes a change in cyclic nucleotide levels in the cytoplasm.

In one embodiment, GPCR-B3 activity is measured by expressing GPCR-B3 in a heterologous cell with a promiscuous G-protein that links the receptor to a phospholipase C signal transduction pathway (*see Offermanns & Simon, J. Biol. Chem.* 270:15175-15180 (1995)). Optionally the cell line is HEK-293 (which does not naturally express GPCR-B3) and the promiscuous G-protein is Gα15 (Offermanns & Simon, *supra*). Modulation of taste transduction is assayed by measuring changes in intracellular Ca<sup>2+</sup> levels, which change in response to modulation of the GPCR-B3 signal transduction pathway via administration of a molecule that associates with GPCR-B3. Changes in

Ca<sup>2+</sup> levels are optionally measured using fluorescent Ca<sup>2+</sup> indicator dyes and fluorometric imaging.

In one embodiment, the changes in intracellular cAMP or cGMP can be measured using immunoassays. The method described in Offermanns & Simon, *J. Biol. Chem.* 270:15175-15180 (1995) may be used to determine the level of cAMP. Also, the  
5 method described in Felley-Bosco *et al.*, *Am. J. Resp. Cell and Mol. Biol.* 11:159-164 (1994) may be used to determine the level of cGMP. Further, an assay kit for measuring cAMP and/or cGMP is described in U.S. Patent 4,115,538, herein incorporated by reference.

10 In another embodiment, phosphatidyl inositol (PI) hydrolysis can be analyzed according to U.S. Patent 5,436,128, herein incorporated by reference. Briefly, the assay involves labeling of cells with <sup>3</sup>H-myoinositol for 48 or more hrs. The labeled cells are treated with a test compound for one hour. The treated cells are lysed and extracted in chloroform-methanol-water after which the inositol phosphates were  
15 separated by ion exchange chromatography and quantified by scintillation counting. Fold stimulation is determined by calculating the ratio of cpm in the presence of agonist to cpm in the presence of buffer control. Likewise, fold inhibition is determined by calculating the ratio of cpm in the presence of antagonist to cpm in the presence of buffer control (which may or may not contain an agonist).

20 In another embodiment, transcription levels can be measured to assess the effects of a test compound on signal transduction. A host cell containing the protein of interest is contacted with a test compound for a sufficient time to effect any interactions, and then the level of gene expression is measured. The amount of time to effect such interactions may be empirically determined, such as by running a time course and  
25 measuring the level of transcription as a function of time. The amount of transcription may be measured by using any method known to those of skill in the art to be suitable. For example, mRNA expression of the protein of interest may be detected using northern blots or their polypeptide products may be identified using immunoassays. Alternatively, transcription based assays using reporter gene may be used as described in U.S. Patent  
30 5,436,128, herein incorporated by reference. The reporter genes can be, e.g., chloramphenicol acetyltransferase, firefly luciferase, bacterial luciferase,  $\beta$ -galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect

reporter via attachment to a second reporter such as green fluorescent protein (*see, e.g.,* Mistili & Spector, *Nature Biotechnology* 15:961-964 (1997)).

The amount of transcription is then compared to the amount of transcription in either the same cell in the absence of the test compound, or it may be compared with the amount of transcription in a substantially identical cell that lacks the protein of interest. A substantially identical cell may be derived from the same cells from which the recombinant cell was prepared but which had not been modified by introduction of heterologous DNA. Any difference in the amount of transcription indicates that the test compound has in some manner altered the activity of the protein of interest.

#### *B. Modulators*

The compounds tested as modulators of GPCR-B3 can be any small chemical compound, or a biological entity, such as a protein, sugar, nucleic acid or lipid. Alternatively, modulators can be genetically altered versions of GPCR-B3. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.

In one embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such "combinatorial chemical libraries" or "ligand libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37:487-493 (1991) and Houghton *et al.*, *Nature* 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (*e.g.*, PCT Publication No. WO 91/19735), encoded peptides (*e.g.*, PCT Publication WO 93/20242), random bio-oligomers (*e.g.*, PCT Publication No. WO 92/00091), benzodiazepines (*e.g.*, U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90:6909-6913 (1993)), vinyllogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116:2661 (1994)), oligocarbamates (Cho *et al.*, *Science* 261:1303 (1993)), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59:658 (1994)), nucleic acid libraries (*see* Ausubel, Berger and Sambrook, all *supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*, Vaughn *et al.*, *Nature Biotechnology*, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et al.*, *Science*, 274:1520-1522 (1996) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus,

Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.*, ComGenex, Princeton, N.J., Tripos, Inc., St. Louis, MO, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

5                    *C. Solid State and soluble high throughput assays*

In one embodiment the invention provide soluble assays using molecules such as a domain such as ligand binding domain, an extracellular domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit  
10 association region, etc.; a domain that is covalently linked to a heterologous protein to create a chimeric molecule; GPCR-B3; or a cell or tissue expressing GPCR-B3, either naturally occurring or recombinant. In another embodiment, the invention provides solid phase based *in vitro* assays in a high throughput format, where the domain, chimeric molecule, GPCR-B3, or cell or tissue expressing GPCR-B3 is attached to a solid phase  
15 substrate.

In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10  
20 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100- about 1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 different compounds is possible using the integrated systems of the invention. More recently, microfluidic  
25 approaches to reagent manipulation have been developed, e.g., by Caliper Technologies (Palo Alto, CA).

The molecule of interest can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage e.g., via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder)  
30 is fixed to a solid support, and the tagged molecule of interest (e.g., the taste transduction molecule of interest) is attached to the solid support by interaction of the tag and the tag binder.

A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a

natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, *etc.*) Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders; *see*, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis MO).

Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherein family, the integrin family, the selectin family, and the like; *see, e.g.*, Pigott & Power, *The Adhesion Molecule Facts Book I* (1993). Similarly, toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, *etc.*), intracellular receptors (e.g. which mediate the effects of various small ligands, including steroids, thyroid hormone, retinoids and vitamin D; peptides), drugs, lectins, sugars, nucleic acids (both linear and cyclic polymer configurations), oligosaccharides, proteins, phospholipids and antibodies can all interact with various cell receptors.

Synthetic polymers, such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.

Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly gly sequences of between about 5 and 200 amino acids. Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Alabama. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.

Tag binders are fixed to solid substrates using any of a variety of methods currently available. Solid substrates are commonly derivatized or functionalized by



exposing all or a portion of the substrate to a chemical reagent which fixes a chemical group to the surface which is reactive with a portion of the tag binder. For example, groups which are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl groups. Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature. *See, e.g.,* Merrifield, *J. Am. Chem. Soc.* 85:2149-2154 (1963) (describing solid phase synthesis of, e.g., peptides); Geysen *et al.*, *J. Immun. Meth.* 102:259-274 (1987) (describing synthesis of solid phase components on pins); Frank & Doring, *Tetrahedron* 44:60316040 (1988) (describing synthesis of various peptide sequences on cellulose disks); Fodor *et al.*, *Science*, 251:767-777 (1991); Sheldon *et al.*, *Clinical Chemistry* 39(4):718-719 (1993); and Kozal *et al.*, *Nature Medicine* 2(7):753759 (1996) (all describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.

#### *D. Computer-based assays*

Yet another assay for compounds that modulate GPCR-B3 activity involves computer assisted drug design, in which a computer system is used to generate a three-dimensional structure of GPCR-B3 based on the structural information encoded by the amino acid sequence. The input amino acid sequence interacts directly and actively with a preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein. The models of the protein structure are then examined to identify regions of the structure that have the ability to bind, e.g., ligands. These regions are then used to identify ligands that bind to the protein.

The three-dimensional structural model of the protein is generated by entering protein amino acid sequences of at least 10 amino acid residues or corresponding nucleic acid sequences encoding a GPCR-B3 polypeptide into the computer system. The amino acid sequence of the polypeptide of the nucleic acid encoding the polypeptide is selected from the group consisting of SEQ ID NOS:1-3 or SEQ ID NOS:4-6 and conservatively modified versions thereof. The amino acid sequence represents the primary sequence or subsequence of the protein, which encodes the structural information of the protein. At least 10 residues of the amino acid sequence (or a nucleotide sequence encoding 10 amino acids) are entered into the computer system from computer

keyboards, computer readable substrates that include, but are not limited to, electronic storage media (e.g., magnetic diskettes, tapes, cartridges, and chips), optical media (e.g., CD ROM), information distributed by internet sites, and by RAM. The three-dimensional structural model of the protein is then generated by the interaction of the amino acid  
5 sequence and the computer system, using software known to those of skill in the art.

The amino acid sequence represents a primary structure that encodes the information necessary to form the secondary, tertiary and quaternary structure of the protein of interest. The software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as "energy  
10 terms," and primarily include electrostatic potentials, hydrophobic potentials, solvent accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secondary  
15 structural model.

The tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure. The user at this point can enter additional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, e.g., cytoplasmic, surface, or  
20 nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.

Once the structure has been generated, potential ligand binding regions are  
25 identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of the GPCR-B3 protein to identify ligands that bind to GPCR-B3. Binding affinity between the protein and ligands is determined using energy terms to  
30 determine which ligands have an enhanced probability of binding to the protein.

Computer systems are also used to screen for mutations, polymorphic variants, alleles and interspecies homologs of GPCR-B3 genes. Such mutations can be associated with disease states or genetic traits. As described above, GeneChip™ and

related technology can also be used to screen for mutations, polymorphic variants, alleles and interspecies homologs. Once the variants are identified, diagnostic assays can be used to identify patients having such mutated genes. Identification of the mutated GPCR-B3 genes involves receiving input of a first nucleic acid or amino acid sequence encoding GPCR-B3, selected from the group consisting of SEQ ID NOS:1-3, or SEQ ID NOS:4-6 and conservatively modified versions thereof. The sequence is entered into the computer system as described above. The first nucleic acid or amino acid sequence is then compared to a second nucleic acid or amino acid sequence that has substantial identity to the first sequence. The second sequence is entered into the computer system in the manner described above. Once the first and second sequences are compared, nucleotide or amino acid differences between the sequences are identified. Such sequences can represent allelic differences in GPCR-B3 genes, and mutations associated with disease states and genetic traits.

#### VIII. Kits

GPCR-B3 and its homologs are a useful tool for identifying taste receptor cells, for forensics and paternity determinations, and for examining taste transduction. GPCR-B3 specific reagents that specifically hybridize to GPCR-B3 nucleic acid, such as GPCR-B3 probes and primers, and GPCR-B3 specific reagents that specifically bind to the GPCR-B3 protein, e.g., GPCR-B3 antibodies are used to examine taste cell expression and taste transduction regulation.

Nucleic acid assays for the presence of GPCR-B3 DNA and RNA in a sample include numerous techniques are known to those skilled in the art, such as Southern analysis, northern analysis, dot blots, RNase protection, S1 analysis, amplification techniques such as PCR and LCR, and *in situ* hybridization. In *in situ* hybridization, for example, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the art of *in situ* hybridization: Singer *et al.*, *Biotechniques* 4:230-250 (1986); Haase *et al.*, *Methods in Virology*, vol. VII, pp. 189-226 (1984); and *Nucleic Acid Hybridization: A Practical Approach* (Hames *et al.*, eds. 1987). In addition, GPCR-B3 protein can be detected with the various immunoassay techniques described above. The test sample is typically compared to both a positive control (e.g., a sample expressing recombinant GPCR-B3) and a negative control.

The present invention also provides for kits for screening for modulators of GPCR-B3. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise any one or more of the following materials: GPCR-B3, reaction tubes, and instructions for testing GPCR-B3 activity. Optionally, the kit  
5 contains biologically active GPCR-B3. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user.

#### **IX. Administration and pharmaceutical compositions**

10 Taste modulators can be administered directly to the mammalian subject for modulation of taste *in vivo*. Administration is by any of the routes normally used for introducing a modulator compound into ultimate contact with the tissue to be treated, e.g., the tongue or mouth. The taste modulators are administered in any suitable manner, optionally with pharmaceutically acceptable carriers. Suitable methods of administering  
15 such modulators are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to  
20 administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences*, 17<sup>th</sup> ed. 1985)).

The taste modulators, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be  
25 administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile  
30 suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by orally, topically, intravenously, intraperitoneally, intravesically or intrathecally. Optionally, the compositions are administered orally or nasally. The formulations of compounds can be presented in unit-dose or multi-dose

sealed containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modulators can also be administered as part a of prepared food or drug.

5 The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial response in the subject over time. The dose will be determined by the efficacy of the particular taste modulators employed and the condition of the subject, as well as the body weight or surface area of the area to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound  
10 or vector in a particular subject.

In determining the effective amount of the modulator to be administered in a physician may evaluate circulating plasma levels of the modulator, modulator toxicities,, and the production of anti-modulator antibodies. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for a typical subject.

15 For administration, taste modulators of the present invention can be administered at a rate determined by the LD-50 of the modulator, and the side-effects of the inhibitor at various concentrations, as applied to the mass and overall health of the subject. Administration can be accomplished via single or divided doses.

20 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily  
25 apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

#### EXAMPLES

30 The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

Example I: Cloning and expression of GPCR-B3

Since taste transduction occurs in taste receptor cells found in taste buds of the tongue and palate epithelium, a full-length cDNA library was generated from rat taste papillae. This library was made by oligo-dT priming of poly-A<sup>+</sup> RNA isolated from several hundreds rat circumvallate papillae using a directional lZAP vector (Stratagene Inc; Hoon & Ryba, *J. Dent. Res.* 76:831-838 (1997)) following standard molecular biology procedures (*see, e.g., Ausubel et al., Current Protocols in Molecular Biology* (1995)). A collection of single-cell and single taste-bud cDNA libraries was also generated from individually isolated taste receptor cells and taste buds from rat and mouse circumvallate, foliate and fungiform papillae according to the method of Dulac & Axel, *Cell* 83:195-206 (1995). Taste buds and single taste receptor cells were isolated by enzymatic digestion and micro-dissection of lingual epithelium from adult rats and mice. To maximize lysis efficiency in the taste bud preparations, the lysis buffer volume was increased 10 fold (Dulac & Axel, *supra*).

GPCR-B3 was isolated from the lZAP circumvallate cDNA library by first generating a subtracted library enriched in sequences expressed in taste tissue. Construction and initial analysis of a taste-receptor cell subtracted cDNA library was as described by Hoon & Ryba, *supra*. Further enrichment of taste-specific transcripts was achieved by dot-blot screening of cDNA clones with non-taste cDNA probes. Non-taste probes included lingual epithelium tissue devoid of taste buds, muscle, liver and brain tissue. The individual hybridization probes were generated by preparing first strand cDNA and labeling it using random priming methods as described in Ausubel *et al., supra*. Hybridization conditions and washes were 65°C, 2x SSC for hybridizations, and 65°C, 0.1x SSC for washing.

All cDNAs that showed taste tissue enrichment in the differential screens with taste and non-taste tissue were picked for DNA sequencing analysis using standard dideoxy-termination methods and an automated ABI sequencing machine. DNA sequences were subjected to data analysis using a variety of homology and structure prediction programs (e.g. blast at <http://www.ncbi.nlm.nih.gov/Tmpred> at <http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>). Individual cDNA clones that encoded novel sequences, sequences with some similarity to known signaling components, sequences with multiple predicted transmembrane domains, or sequences with known motifs such as SH2, SH3, PDZ, etc (see for example pfam at <http://pfam.wustl.edu/>) were chosen as candidates for further analysis.

Candidate cDNAs were assayed for taste-cell expression by *in situ* hybridization to tissue sections of rat tongue. Tissue was obtained from adult rats. Fresh frozen sections (14 mm) were attached to silanized slides and prepared for *in situ* hybridization as described by Ryba & Tirindelli, *Neuron* 19:371-379 (1997). All *in situ* hybridizations were carried out at high stringency (5x SSC, 50 % formamide, 72 °C). For single-label detection, signals were developed using alkaline-phosphatase conjugated antibodies to digoxigenin and standard chromogenic substrates (Boehringer Mannheim) as described by Ryba & Tirindelli, *supra*. Partial DNA sequencing reactions were performed on ~2000 subtracted and single-cell cDNA clones, and *in situ* hybridizations were carried out with ~400 different candidate cDNAs. This screen identified a number of genes expressed in taste receptor cells including a single clone encoding a 3' fragment of GPCR-B3.

Full-length rat GPCR-B3 was isolated from the lZAP rat circumvallate cDNA library following standard plaque hybridization protocols (Ausubel *et al.*, *supra*). Approximately 2.5 x10<sup>6</sup> clones were plated at high density on LB plates (~100,000 phage/plate) and replica filters were hybridized with a radiolabeled GPCR-B3 probe at high stringency (65°C, 2x SSC). Positive clones were picked, retested, purified and characterized by DNA restriction mapping and sequencing analysis. Several full-length GPCR-B3 clones were isolated and characterized (see SEQ ID NOS:4-6 and the amino acid sequences that they encode, SEQ ID NOS:1-3).

The mouse interspecies homolog of rat GPCR-B3 was isolated by screening a mouse genomic Bac and l library (Genome Systems) at low and moderate stringency (48°C, 7x SSC and 55°C, 5x SSC). The clones were characterized by restriction mapping and DNA sequencing. A mouse cDNA was isolated by performing RACE reactions (Marathon Kit, Clontech) using first-strand cDNA prepared from RNA isolated from mouse circumvallate and foliate papillae. The human homolog of GPCR-B3 was isolated from a human testis library (Clontech Inc.) following the observation that other sensory receptors such as olfactory and visual receptors are expressed in testis (Axel & Dulac, *supra*). See Figure 1 for a topological map of GPCR-B3, showing the extracellular domain, seven transmembrane domains, and an intracellular or C-terminal domain.

Example II: Western blot and *in situ* analysis

To demonstrate specific expression of GPCR-B3 protein in taste cells, antibodies were generated against short peptides and GPCR-B3 fusion proteins. The peptides consisted of 18 amino acid residues from the N- or C-terminal end of the GPCR-B3 predicted protein (*see, e.g.*, SEQ ID NO:1 and 2). The fusion proteins consisted of GST-fusion polypeptides encompassing the entire N-terminal domain or the last 3 predicted transmembrane segments plus the C-term region. Fusions were generated using standard molecular techniques (Harlow & Lane, *Antibodies* (1988)). Peptides were fused to carrier proteins, immunized into rabbits, and the serum affinity purified and assayed as described by Cassill *et al.*, *Proc. Nat'l Acad. Sci. USA* 88:11067-11070 (1991)).

Antibodies were tested for specificity by western-blot analysis of protein homogenates from circumvallate or fungiform papillae. The blots also contained liver and brain protein extracts as negative controls. For immunohistochemistry, frozen sections were prepared as described by Ryba & Tirindelli, *supra* for *in situ* hybridizations, except that blocking reactions used 10 % donkey immunoglobulin, 1 % bovine serum albumin, 0.3% Triton X-100. Sections were incubated in the appropriate dilution of anti-TR1 (1:100) for 12-18 hrs., and detected using fluorescein-conjugated donkey anti-rabbit secondary antibodies (Jackson Immunolaboratory). Taste buds were counter-stained with the F-actin marker BODIPYRTR-X phalloidin (Molecular Probes). As a control for these studies, anti-NCAM antibodies were also used. Fluorescent images were obtained using a Leica TSC confocal microscope with an argon-krypton laser. Pre-treatment of the antibodies with the peptide immunogen abolished staining. See Figures 2 and 3 for western blot and *in situ* analysis, respectively.



WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70% amino acid identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
2. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a receptor that specifically binds to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
3. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a receptor that has G-coupled protein receptor activity.
4. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a receptor comprising an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
5. The isolated nucleic acid sequence of claim 1, wherein the nucleic acid comprises a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.
6. The isolated nucleic acid of claim 1, wherein the nucleic acid is from a human, a mouse, or a rat.
7. The isolated nucleic acid of claim 1, wherein the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to the same sequence as degenerate primer sets encoding amino acid sequences selected from the group consisting of:  
IAWDWNGPKW (SEQ ID NO:7) and  
LPENYNEAKC (SEQ ID NO:8).
8. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a receptor having a molecular weight of about between 92 kDa to about 102 kDa.

9. An isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, wherein the nucleic acid specifically hybridizes under highly stringent conditions to a nucleic acid having the sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.

5

10. An isolated nucleic acid encoding a sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, wherein the nucleic acid selectively hybridizes under moderately stringent hybridization conditions to a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6.

10

11. An isolated nucleic acid encoding an extracellular domain of a sensory transduction G-protein coupled receptor, the extracellular domain having greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1.

15

12. The isolated nucleic acid of claim 11, wherein the nucleic acid encodes the extracellular domain linked to a nucleic acid encoding a heterologous polypeptide, forming a chimeric polypeptide.

20

13. The isolated nucleic acid of claim 11, wherein the nucleic acid encodes the extracellular domain of SEQ ID NO:1.

14. An isolated nucleic acid encoding a transmembrane domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the transmembrane domain of SEQ ID NO:1.

25

15. The isolated nucleic acid of claim 14, wherein the nucleic acid encodes the transmembrane domain linked to a nucleic acid encoding a heterologous polypeptide, forming a chimeric polypeptide.

30

16. The isolated nucleic acid of claim 14, wherein the nucleic acid encodes the transmembrane domain of SEQ ID NO:1.

17. The isolated nucleic acid of claim 14, wherein the nucleic acid further encodes a cytoplasmic domain comprising greater than about 70% amino acid identity to the cytoplasmic domain of SEQ ID NO:1.

5

18. The isolated nucleic acid of claim 17, wherein the nucleic acid encodes the cytoplasmic domain of SEQ ID NO:1.

19. An isolated sensory transduction G-protein coupled receptor, the  
10 receptor comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

20. The isolated receptor of claim 19, wherein the receptor specifically binds to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:2, or SEQ ID  
15 NO:3.

21. The isolated receptor of claim 19, wherein the receptor has G-protein coupled receptor activity.

22. The isolated receptor of claim 19, wherein the receptor has an  
20 amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

23. The isolated receptor of claim 19, wherein the receptor is from a human, a rat, or a mouse.

25

24. An isolated polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor, the extracellular domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1.

30

25. The isolated polypeptide of claim 24, wherein the polypeptide encodes the extracellular domain of SEQ ID NO:1.

26. The isolated polypeptide of claim 24, wherein the extracellular domain is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

5 27. An isolated polypeptide comprising a transmembrane domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the transmembrane domain of SEQ ID NO:1.

10 28. The isolated polypeptide of claim 27, wherein the polypeptide encodes the transmembrane domain of SEQ ID NO:1.

29. The isolated polypeptide of claim 27, further comprising a cytoplasmic domain comprising greater than about 70% amino acid identity to the  
15 cytoplasmic domain of SEQ ID NO:1.

30. The isolated polypeptide of claim 29, wherein the polypeptide encodes the cytoplasmic domain of SEQ ID NO:1.

20 31. The isolated polypeptide of claim 27, wherein the transmembrane domain is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

25 32. The isolated polypeptide of claim 31, wherein the chimeric polypeptide has G-protein coupled receptor activity.

33. An antibody that selectively binds to the receptor of claim 19.

34. An expression vector comprising the nucleic acid of claim 1.

30

35. A host cell transfected with the vector of claim 34.

36. A method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of:

- (i) contacting the compound with a polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor, the extracellular domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and
- 5 (ii) determining the functional effect of the compound upon the extracellular domain.

37. The method of claim 36, wherein the polypeptide is a sensory transduction G-protein coupled receptor, the receptor comprising greater than about 70% amino acid identity to a polypeptide encoding SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

10

38. The method of claim 37, wherein the polypeptide comprises an extracellular domain that is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

15

39. The method of claim 37 or 38, wherein the polypeptide has G-protein coupled receptor activity.

40. The method of claim 36, wherein the extracellular domain is linked to a solid phase.

20

41. The method of claim 40, wherein the extracellular domain is covalently linked to a solid phase.

25

42. The method of claim 37 or 38, wherein functional effect is determined by measuring changes in intracellular cAMP, IP3, or  $\text{Ca}^{2+}$ .

43. The method of claim 36, wherein the functional effect is a chemical effect.

30

44. The method of claim 36, wherein the functional effect is a physical effect.

45. The method of claim 36, wherein the functional effected is determined by measuring binding of the compound to the extracellular domain.

46. The method of claim 36, wherein the polypeptide is recombinant.

5

47. The method of claim 36, wherein the polypeptide is from a rat, a mouse, or a human.

48. The method of claim 37, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

10

49. The method of claim 37 or 38, wherein the polypeptide is expressed in a cell or cell membrane.

15

50. The method of claim 49, wherein the cell is a eukaryotic cell.

51. A method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of:

(i) contacting the compound with a polypeptide comprising an extracellular domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and

20

(ii) determining the functional effect of the compound upon the transmembrane domain.

25

52. The method of claim 51, wherein the polypeptide comprises an transmembrane domain that is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

30

53. The method of claim 52, wherein the chimeric polypeptide has G-protein coupled receptor activity.

54. The method of claim 51, wherein the functional effect is determined by measuring changes in intracellular cAMP, IP3, or Ca<sup>2+</sup>.

55. The method of claim 51, wherein the functional effect is a chemical effect.
- 5 56. The method of claim 51, wherein the functional effect is a physical effect.
57. The method of claim 51, wherein the polypeptide is recombinant.
- 10 58. The method of claim 51, wherein the polypeptide is from a rat, a mouse, or a human.
59. The method of claim 51 or 52, wherein the polypeptide is expressed in a cell or cell membrane.
- 15 60. The method of claim 59, wherein the cell is a eukaryotic cell.
61. A method of making a sensory transduction G-protein coupled receptor, the method comprising the step of expressing the receptor from a recombinant expression vector comprising a nucleic acid encoding the receptor, wherein the amino acid sequence of the receptor comprises greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
- 20 62. A method of making a recombinant cell comprising a sensory transduction G-protein coupled receptor, the method comprising the step of transducing the cell with an expression vector comprising a nucleic acid encoding the receptor, wherein the amino acid sequence of the receptor comprises greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
- 25 63. A method of making an recombinant expression vector comprising a nucleic acid encoding a sensory transduction G-protein coupled receptor, the method comprising the step of ligating to an expression vector a nucleic acid encoding the receptor, wherein the amino acid sequence of the receptor comprises greater than about
- 30

70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.



## AMENDED CLAIMS

[received by the International Bureau on 11 November 1999 (11.11.99);  
original claim 51 amended; remaining claims unchanged (1 page)]

45. The method of claim 36, wherein the functional effect is determined by measuring binding of the compound to the extracellular domain.

46. The method of claim 36, wherein the polypeptide is recombinant.

5

47. The method of claim 36, wherein the polypeptide is from a rat, a mouse, or a human.

48. The method of claim 37, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

10

49. The method of claim 37 or 38, wherein the polypeptide is expressed in a cell or cell membrane.

15

50. The method of claim 49, wherein the cell is a eukaryotic cell.

51. A method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of:

(i) contacting the compound with a polypeptide comprising a transmembrane domain of a sensory transduction G-protein coupled receptor, the transmembrane domain comprising greater than about 70% amino acid sequence identity to the transmembrane domain of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and

(ii) determining the functional effect of the compound upon the transmembrane domain.


20


52. The method of claim 51, wherein the polypeptide comprises an transmembrane domain that is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide.

25

53. The method of claim 52, wherein the chimeric polypeptide has G-protein coupled receptor activity.

54. The method of claim 51, wherein the functional effect is determined by measuring changes in intracellular cAMP, IP3, or Ca<sup>2+</sup>.





m=markers

tb=taste buds

nt-t=non-taste from tongue

nt=non-taste tissue

FUNGIFORM

FUNGIFORM

B3-13

B3-13


FOLIATE

CIRCUMVALLATE

B3

B3

# PLC



## SEQUENCE LISTING

Rat GPCR-B3 amino acid sequence--SEQ ID NO:1

MLFWAAHLLLSLQLVYCWAFSCQRTESSPGFSLPGDFLLAGLFSLHGDCLQVRHRPLVTS  
 5 CDRPDSFNHGHGYHLFQAMRFTVEEINNSSALLPNITLGYELYDVCSESANVYATLRVLAL  
 QGPRHIEIQKDLRNHSSKVVAFIGPDNTDHAVTTAALLGPFLMPLVSYEASSVVLAKRK  
 FPSFLRTVPSDRHQVEVMVQLLQSFGVWVWISLIGSYGDYQQLGVQALEELAVPRGICVAF  
 KDIVPFSARVGDPQMOSMMQHLAQARTTVVVVFSNRHLARVFFRSVVLNLTGKVVVASE  
 DWAISTYITSVTGIQIGITVLGVAVQQRQVPGLKEFEESYVRAVTAAPSACPEGSWCSTN  
 10 QLCRECHTFTTRNMPTLGAFMSAAAYRVYEAVYAVAHGLHQLLGCTSEICSRGPVYPWQL  
 LQQIYKVNFLHENTVAFDDNGDTLGYDYIIAWDWNPEWTFEIIIGSASLSPVHLDINKT  
 KIQWHGKNNQVPVSVCTTDCLAGHHRVVVGSHHCCFECVPCEAGTFLNMSSELHICQPCGT  
 EEWAPKESTTCFPRTVEFLAWHEPISLVLIAANTLLLLLLVGTAGLFAWHFHTPVVRSAG  
 GRLCFLMLGSLVAGSCSFYSFFGEPTVPACLLRQPLFSLGFAIFLSCLTIRSFQLVIFK  
 15 FSTKVPTFYRTWAQNHGAGLFVIVSSTVHLLICLTWLVMTWTPRPTREYQRFPHLVILECT  
 EVNSVGFLLAFTHNILLSISTFVCSYLGKELPENYNEAKCVTFSLLLNFVSWIAFFTMAS  
 IYQGSYLPVNVLAGLTTLGGGFSGYFLPKCYVILCRPELNNTTEHFQASIQDYTRRCGT

Mouse GPCR-B3 amino acid sequence--SEQ ID NO:2

MLFWAAHLLLSLQLAVAYCWAFSCQRTESSPGFSLPGDFLLAGLFSLHADCLQVRHRPLV  
 20 TSCDRSDSFNHHGYHLFQAMRFTVEEINNSTALLPNITLGYELYDVCSESSNVYATLRVP  
 AQQGTGHLEMQRDLRNHSSKVVALIGPDNTDHAVTTAALLSPFLMPLVSYEASSVILSGK  
 RKFPSFLRTIPSDKYQVEVIVRLLQSFGVWVWISLVGSYGDYQQLGVQALEELATPRGICV  
 AFKDVVPLSAQAGDPRMQRMMLRLARARTTVVVVFSNRHLAGVFFRSVVLNLTGKVVIA  
 25 SEDWAISTYITNVPGIQIGITVLGVAIQQRQVPGLKEFEESYVQAVMGAPRTCPEGSWCG  
 TNQLCRECHAFTTWNMPPELGAFMSAAAYNVYEAVYAVAHGLHQLLGCTSGTCARGPVYPW  
 QLLQQIYKVNFLHKKTVAFDDKGDPLGYDYIIAWDWNPEWTFEIVIGSASLSPVHLDIN  
 KTKIQWHGKNNQVPVSVCTRDCLEGHRLVMGSHHCCFECMPCEAGTFLNTSELHTCQPC  
 GTEEWAPEGSSACFSRTVEFLGWHEPISLVLLAANTLLLLLLIGTAGLFAWRLHTPVVRS  
 30 AGGRLCFLMLGSLVAGSCSLYSFFGKPTVPACLLRQPLFSLGFAIFLSCLTIRSFQLVII  
 FKFSTKVPTFYHTWAQNHGAGIFVIVSSTVHLFLCLTWLMTWTPRPTREYQRFPHLVILE  
 CTEVNSVGFLVAFHNILLSISTFVCSYLGKELPENYNEAKCVTFSLLLHFVSWIAFFTM  
 SSIYQGSYLPVNVLAGLATLGGGFSGYFLPKCYVILCRPELNNTTEHFQASIQDYTRRCG  
 TT

Human GPCR-B3 amino acid sequence--SEQ ID NO:3

RSCSFNEHGYHLFQAMRLGVEEINNSTALLPNITLGYQLYDVCSDSANVYATLRVLSLPG  
 QHHIELQGDLHLHYSPTVLAVIGPDSTNRAATTAALLSPFLVHISYAASSETLSVKRQYPS  
 5 FLRTIPNDKYQVETMVLLLQKFGWTWISLVGSSDDYGQLGVQALENQALVRGICIAFKDI  
 MPFSAQVGDERMQCLMRHLAQAGATVVVVFSSRQLARVFFESVVLTNLTGKVWVASEAWA  
 LSRHITGVPGIQRIGMVLGVAIQKRAVPGLKAFEEAYARADKEAPRPCHKGSWCSSNQLC  
 RECQAFMAHTMPKLKAFSMSSAYNAYRAVYAVAHGLHQLLGCASELCSRGRVYPWQLLEQ  
 IHKVHFLHLKDTVAFNDNRDPLSSYNI IAWDWNPKWTFITVLGSSTWSPQLNINETKIQ  
 10 WHGKNHQVPKSVCSDDCLEGHQRVVTGFHCCFECVPCGAGTFLNKSELYRCQPCGTEEW  
 APEGSQTCFPRTVVFLALREHTSWVLLAANTLLLLLLLGTAGLFAWHLDTPVVRSAGGRL  
 CFLMLGSLAAGSGSLYGFFGEPTRPACLLRQALFALGFTIFLSCLTVRSFQLIIIFKFST  
 KVPTFYHAWVQNHGAGLFVMISSAAQLLICLTWLVVWTPLPAREYQRFPHLVMLECTETN  
 SLGFILAFLYNGLLSISAFACSYLGKDLPENYNEAKCVTFSLLENFVSWIAFFTASVYD  
 15 GKYLPAANMMAGLSSLSGGGYFLPKCYVILCRPDLNSTEHFQASIQDYTRRCGST

Rat GPCR-B3 nucleotide sequence--SEQ ID NO:4

ATTCACATCAGAGCTGTGCTCAGCCATGCTGGGCAGAGGGACGACGGCTGGCCAGCATGC  
 TCTTCTGGGCTGCTCACCTGCTGCTCAGCCTGCAGTTGGTCTACTGCTGGGCTTTCAGCT  
 20 GCCAAAGGACAGAGTCCTCTCCAGGCTTCAGCCTTCCTGGGGACTTCCTCCTTGCAGGTC  
 TGTCTCTCCCTCCATGGTGACTGTCTGCAGGTGAGACACAGACCTCTGGTGACAAGTTGTG  
 ACAGGCCCCGACAGCTTCAACGGCCATGGCTACCACCTCTTCCAAGCCATGCGGTTCACTG  
 TTGAGGAGATAAACAACCTCCTCGGCCCTGCTTCCCAACATCACCTTGGGGTATGAGCTGT  
 ACGACGTGTGCTCAGAACTGCCAATGTGTATGCCACCCTGAGGGTGCTTGCCCTGCAAG  
 25 GGCCCCGCCACATAGAGATACAGAAAGACCTTCGCAACCACTCCTCCAAGGTGGTGGCCT  
 TCATCGGGCCTGACAACACTGACCACGCTGTCACTACCGCTGCCTTGCTGGGTCTTTCC  
 TGATGCCCCCTGGTCAGCTATGAGGCAAGCAGCGTGGTACTCAGTGCCAAGCGCAAGTTCC  
 CGTCTTTCTTCGTACCGTCCCCAGTGACCGGCACCAGGTGGAGGTCATGGTGCAGCTGC  
 TGCAGAGTTTTGGGTGGGTGTGGATCTCGCTCATTGGCAGCTACGGTGATTACGGGCAGC  
 30 TGGGTGTGCAGGCGCTGGAGGAGCTGGCCGTGCCCCGGGCATCTGCGTCGCCTTCAAGG  
 ACATCGTGCCTTTCTCTGCCCCGGTGGGTGACCCGAGGATGCAGAGCATGATGCAGCATC  
 TGGCTCAGGCCAGGACCACCGTGGTTGTGGTCTTCTCTAACCGGCACCTGGCTAGAGTGT  
 TCTTCAGGTCCGTGGTGCTGGCCAACCTGACTGGCAAAGTGTGGGTGCGCTCAGAAGACT  
 GGGCCATCTCCACGTACATCACCAGCGTGACTGGGATCCAAGGCATTGGGACGGTGCTCG



GTGTGGCCGTCCAGCAGAGACAAGTCCCTGGGCTGAAGGAGTTTGAGGAGTCTTATGTCA  
GGGCTGTAACAGCTGCTCCCAGCGCTTGCCCGGAGGGGTCTTGGTGCAGCACTAACCAGC  
TGTGCCGGGAGTGCCACACGTTACGACTCGTAACATGCCCACGCTTGGAGCCTTCTCCA  
TGAGTGCCGCCTACAGAGTGTATGAGGCTGTGTACGCTGTGGCCACGGCCTCCACCAGC  
5 TCCTGGGATGTACTTCTGAGATCTGTTCCAGAGGCCAGTCTACCCCTGGCAGCTTCTTC  
AGCAGATCTACAAGGTGAATTTTCTTCTACATGAGAATACTGTGGCATTGTGATGACAACG  
GGGACACTCTAGGTTACTACGACATCATCGCCTGGGACTGGAATGGACCTGAATGGACCT  
TTGAGATCATTGGCTCTGCCTCACTGTCTCCAGTTCATCTGGACATAAATAAGACAAAAA  
TCCAGTGGCACGGGAAGAACAATCAGGTGCCTGTGTACAGTGTGTACCACGGACTGTCTGG  
10 CAGGGCACCACAGGGTGGTTGTGGGTTCACCACTGCTGCTTTGAGTGTGTGCCCTGCG  
AAGCTGGGACCTTTCTCAACATGAGTGAGCTTCACATCTGCCAGCCTTGTGGAACAGAAG  
AATGGGCACCCAAGGAGAGCACTACTTGCTTCCCACGCACGGTGGAGTTCTTGGCTTGGC  
ATGAACCCATCTCTTTGGTGCTAATAGCAGCTAACACGCTATTGCTGCTGCTGCTGGTTG  
GGACTGCTGGCCTGTTTGCCTGGCATTTCACACACCTGTAGTGAGGTGAGCTGGGGGTA  
15 GGCTGTGCTTCCTCATGCTGGGTTCCTGGTGGCCGGAAGTTGCAGCTTCTATAGCTTCT  
TCGGGGAGCCACGGTGCCCGCGTGCTTGCCTGCGTCAGCCCCTCTTTCTCTCGGGTTTG  
CCATCTTCCTCTCCTGCCTGACAATCCGCTCCTTCCAAGTGGTCATCATCTTCAAGTTTT  
CTACCAAGGTGCCCACATTCTACCGTACCTGGGCCCCAAAACCATGGTGCAGGTCTATTG  
TCATTGTCAGCTCCACGGTCCATTTGCTCATCTGTCTCACATGGCTTGTAAATGTGGACCC  
20 CACGACCCACCAGGGAATACCAGCGCTTCCCCCATCTGGTGATTCTCGAGTGCACAGAGG  
TCAACTCTGTAGGCTTCCTGTTGGCTTTCACCCACAACATTCTCCTCTCCATCAGTACCT  
TCGTCTGCAGCTACCTGGGTAAGGAACTGCCAGAGAACTATAATGAAGCCAAATGTGTCA  
CCTTCAGCCTGCTCCTCAACTTCGTATCCTGGATCGCCTTCTTACCATGGCCAGCATTT  
ACCAGGGCAGCTACCTGCCTGCGGTCAATGTGCTGGCAGGGCTGACCACACTGAGCGGCG  
25 GCTTCAGCGGTTACTTCCTCCCAAGTGCTATGTGATTCTCTGCCGTCCAGAACTCAACA  
ATACAGAACTTTTCAAGCCTCCATCCAGGACTACACGAGGCGCTGCGGCACTACCTGAT  
CCACTGGAAAGGTGCAGACGGGAAGGAAGCCTCTCTTCTTGTGCTGAAGGTGGCGGGTCC  
AGTGGGGCCGAGAGCTTGAGGTGTCTGGGAGAGCTCCGGCACAGCTTACGATGTATAAGC  
ACGCGGAAGAATCCAGTGCAATAAAGACGGGAAGTGTGAAAAAAAAAAAAAAAAAAAAA  
30 AAAAAAAAAA

Mouse GPCR-B3 nucleotide sequence--SEQ ID NO:5

TTTGGCCAGCATGCTTTTCTGGGCAGCTCACCTGCTGCTCAGCCTGCAGCTGGCCGTTGC  
TTACTGCTGGGCTTTCAGCTGCCAAAGGACAGAATCCTCTCCAGGTTTCAGCCTCCCTGG

GGACTTCCTCCTGGCAGGCCTGTTCTCCCTCCATGCTGACTGTCTGCAGGTGAGACACAG  
ACCTCTGGTGACAAGTTGTGACAGGTCTGACAGCTTCAACGGCCATGGCTATCACCTCTT  
CCAAGCCATGCGGTTACCCGTTGAGGAGATAAACTCCACAGCTCTGCTTCCCAACAT  
CACCTGGGGTATGAACTGTATGACGTGTGCTCAGAGTCTTCCAATGTCTATGCCACCCT  
5 GAGGGTGCCCGCCAGCAAGGGACAGGCCACCTAGAGATGCAGAGAGATCTTCGCAACCA  
CTCCTCCAAGGTGGTGGCACTCATTGGGCCTGATAACACTGACCACGCTGTCACCACTGC  
TGCCCTGCTGAGCCCTTTTCTGATGCCCCTGGTCAGCTATGAGGCGAGCAGCGTGATCCT  
CAGTGGGAAGCGCAAGTCCCGTCCTTCTTGCGCACCATCCCCAGCGATAAGTACCAGGT  
GGAAGTCATAGTGGGCTGCTGCAGAGCTTCGGCTGGGTCTGGATCTCGCTCGTTGGCAG  
10 CTATGGTGACTACGGGCAGCTGGGCGTACAGGCGCTGGAGGAGCTGGCCACTCCACGGGG  
CATCTGCGTCGCCTTCAAGGACGTGGTGCCTCTCTCCGCCAGGCGGGTGACCCAAGGAT  
GCAGCGCATGATGCTGCGTCTGGCTCGAGCCAGGACCACCGTGGTCTGGTCTTCTCTAA  
CCGGCACCTGGCTGGAGTGTCTTCAGGTCTGTGGTGCTGGCCAACTGACTGGCAAAGT  
GTGGATCGCCTCCGAAGACTGGGCCATCTCCACGTACATACCAATGTGCCCCGGGATCCA  
15 GGGCATTGGGACGGTGCTGGGGGTGGCCATCCAGCAGAGACAAGTCCCTGGCCTGAAGGA  
GTTTGAAGAGTCCTATGTCCAGGCAGTGATGGGTGCTCCCAGAACTTGCCCAGAGGGGTG  
CTGGTGCGGCACTAACCAGCTGTGCAGGGAGTGTACGCTTTCACGACATGGAACATGCC  
CGAGCTTGGAGCCTTCTCCATGAGCGCTGCCTACAATGTGTATGAGGCTGTGTATGCTGT  
GGCCACGGCCTCCACCAGCTCCTGGGATGTACCTCTGGGACCTGTGCCAGAGGGCCCAGT  
20 CTACCCCTGGCAGCTTCTTCAGCAGATCTACAAGGTGAATTTCTTCTACATAAGAAGAC  
TGTAGCATTTCGATGACAAGGGGGACCTCTAGGTTATTATGACATCATCGCCTGGGACTG  
GAATGGACCTGAATGGACCTTTGAGGTCAATTGGTTCTGCCTCACTGTCTCCAGTTCATCT  
AGACATAAATAAGACAAAATCCAGTGGCACGGGAAGAACAATCAGGTGCCTGTGTCACT  
GTGTACCAGGGACTGTCTCGAAGGGCACCAAGGTTGGTCATGGGTTCCCACCACTGCTG  
25 CTTTCGAGTGCATGCCCTGTGAAGCTGGGACATTTCTCAACACGAGTGAGCTTACACCTG  
CCAGCCTTGTGGAACAGAAGAATGGGCCCCCTGAGGGGAGCTCAGCCTGCTTCTCACGCAC  
CGTGAGATTCTTGGGGTGGCATGAACCCATCTCTTTGGTGCTATTAGCAGCTAACACGCT  
ATTGCTGCTGCTGCTGATTGGGACTGCTGGCCTGTTTGCCTGGCGTCTTACACGCCTGT  
TGTGAGGTCAGCTGGGGGTAGGCTGTGCTTCCTCATGCTGGGTTCTTGGTAGCTGGGAG  
30 TTGCAGCCTCTACAGCTTCTTCGGGAAGCCACGGTGCCCGCTGCTTGCTGCGTCAGCC  
CCTCTTTTCTCTCGGGTTTGCCATTTTCTCTCCTGTCTGACAATCCGCTCCTTCCAAC  
GGTCATCATCTTCAAGTTTTCTACCAAGGTACCCACATTCTACCACACTTGGGCCCCAAA  
CCATGGTGCCGGAATATTTCGTCAATTGTCAGCTCCACGGTCCATTTGTTCTCTGTCTCAC  
GTGGCTTGCAATGTGGACCCACGGCCACAGGGAGTACCAGCGCTTCCCCCATCTGGT

GATTCTTGAGTGCACAGAGGTCAACTCTGTGGGCTTCCTGGTGGCTTTCGCACACAACAT  
CCTCCTCTCCATCAGCACCTTTGTCTGCAGCTACCTGGGTAAGGAACTGCCGGAGAACTA  
TAACGAAGCCAAATGTGTCACCTTCAGCCTGCTCCTCCACTTCGTATCCTGGATCGCTTT  
CTTCACCATGTCCAGCATTTACCAGGGCAGCTACCTACCCGCGGTCAATGTGCTGGCAGG  
5 GCTGGCCACTCTGAGTGGCGGCTTCAGCGGCTATTTCCCTCCCTAAATGCTACGTGATTCT  
CTGCCGTCCAGAACTCAACAACACAGAACTTTTCAGGCCTCCATCCAGGACTACACGAG  
GCGCTGCGGCACTACCTGAGGCGCTGCGGCACTACCTGAGGCGCTGCGGCACTACCTGA

Human GPCR-B3 nucleotide sequence--SEQ ID NO:6

10 AGGTCTTGTAGCTTCAATGAGCATGGCTACCACCTCTTCCAGGCTATGCGGCTTGGGGTT  
GAGGAGATAAACTCCACGGCCCTGCTGCCAACATCACCTGGGGTACCAGCTGTAT  
GATGTGTGTTCTGACTCTGCCAATGTGTATGCCACGCTGAGAGTGCTCTCCCTGCCAGGG  
CAACACCACATAGAGCTCCAAGGAGACCTTCTCCACTATTTCCCTACGGTGCTGGCAGTG  
ATTGGGCCTGACAGCACCAACCGTGCTGCCACCACAGCCGCCCTGCTGAGCCCTTTCCCTG  
15 GTGCATATTAGCTATGCGGCCAGCAGCGAGACGCTCAGCGTGAAGCGGCAGTATCCCTCT  
TTCCTGCGCACCATCCCCAATGACAAGTACCAGGTGGAGACCATGGTGCTGCTGCTGCAG  
AAGTTCGGGTGGACCTGGATCTCTCTGGTTGGCAGCAGTGACGACTATGGGCAGCTAGGG  
GTGCAGGCACTGGAGAACCAGGCCCTGGTCAGGGGCATCTGCATTGCTTTCAAGGACATC  
ATGCCCTTCTCTGCCCAGGTGGGCGATGAGAGGATGCAGTGCCTCATGCGCCACCTGGCC  
20 CAGGCCGGGGCCACCGTCGTGGTTGTTTTTCCAGCCGGCAGTTGGCCAGGGTGTTTTTC  
GAGTCCGTGGTGCTGACCAACCTGACTGGCAAGGTGTGGGTGCGCTCAGAAGCCTGGGCC  
CTCTCCAGGCACATCACTGGGGTGCCCGGGATCCAGCGCATTTGGGATGGTGCTGGGCGTG  
GCCATCCAGAAGAGGGCTGTCCCTGGCCTGAAGGCGTTTGAAGAAGCCTATGCCCGGGCA  
GACAAGGAGGCCCCTAGGCCTTGACAAGGGCTCCTGGTGCAGCAGCAATCAGCTCTGCA  
25 GAGAATGCCAAGCTTTCATGGCACACAGATGCCCAAGCTCAAAGCCTTCTCCATGAGTT  
CTGCCTACAACGCATACCGGGCTGTGTATGCGGTGGCCCATGGCCTCCACCAGCTCCTGG  
GCTGTGCCTCTGAGCTCTGTTCCAGGGGCGGAGTCTACCCCTGGCAGCTTTTGAGCAGA  
TCCACAAGGTGCATTTCTTCTACACAAGGACACTGTGGCGTTTAATGACAACAGAGATC  
CCCTCAGTAGCTATAACATAATTGCCTGGGACTGGAATGGACCCAAGTGGACCTTCACGG  
30 TCCTCGGTTCCCTCCACATGGTCTCCAGTTCAGCTAAACATAAATGAGACCAAAATCCAGT  
GGCACGGAAAGAACCACCAGGTGCCTAAGTCTGTGTGTTCCAGCGACTGTCTTGAAGGGC  
ACCAGCGAGTGGTTACGGGTTTCCATCACTGCTGCTTTGAGTGTGTGCCCTGTGGGGCTG  
GGACCTTCCTCAACAAGAGCGAGCTCTACAGATGCCAGCCTTGTGGAACAGAAGAGTGGG  
CACCTGAGGGAAGCCAGACCTGCTTCCCGCGCACTGTGGTGTTTTTGGCTTTGCGTGAGC

ACACCTCTTGGGTGCTGCTGGCAGCTAACACGCTGCTGCTGCTGCTGCTGCTTGGGACTG  
CTGGCCTGTTTGCCTGGCACCTAGACACCCCTGTGGTGAGGTGAGCAGGGGGCCGCCTGT  
GCTTTCTTATGCTGGGCTCCCTGGCAGCAGGTAGTGGCAGCCTCTATGGCTTCTTTGGGG  
AACCCACAAGGCCTGCGTGCTTGCTACGCCAGGCCCTCTTTGCCCTTGTTTTACCATCT  
5 TCCTGTCTGCTGACAGTTCGCTCATTCCAATAATCATCATCTTCAAGTTTTCCACCA  
AGGTACCTACATTCTACCACGCCTGGGTCCAAAACCACGGTGCTGGCCTGTTTGTGATGA  
TCAGCTCAGCGGCCAGCTGCTTATCTGTCTAACTTGGCTGGTGGTGTGGACCCCACTGC  
CTGCTAGGGAATACCAGCGCTTCCCCCATCTGGTGATGCTTGAGTGCACAGAGACCAACT  
CCCTGGGCTTCATACTGGCCTTCCTCTACAATGGCCTCCTCTCCATCAGTGCCTTTGCCT  
10 GCAGCTACCTGGGTAAGGACTTGCCAGAGAACTACAACGAGGCCAAATGTGTACCTTCA  
GCCTGCTCTTCAACTTCGTGTCCTGGATCGCCTTCTTCACCACGGCCAGCGTCTACGACG  
GCAAGTACCTGCCTGCGGCCAACATGATGGCTGGGCTGAGCAGCCTGAGCAGCGGCTTCG  
GTGGGTATTTTCTGCCTAAGTGCTACGTGATCCTCTGCCGCCAGACCTCAACAGCACAG  
AGCACTTCCAGGCCTCCATTAGGACTACACGAGGCGCTGCGGCTCCACCTGA

15

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/17099

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07K 1/00; C07H 21/04; C12P 21/06

US CL : 530/350; 536/23.5; 435/691

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.5; 435/691

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: Biosis, Medline

Search terms: taste receptor, gustatory receptor, cDNA, clone, DNA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | US 4,146,501 A (HENKIN) 27 March 1979.   | 1-32, 34, 35, 61-63   |
| A         | US 5,688,662 A (MARGOLSKEE) 18 November 1997.  | 1-32, 34, 35, 61-63   |
| A         | MARGOLSKEE, R.F. The molecular biology of taste transduction. BioEssays. October 1993, Vol. 15, No. 10, pages 645-650.   | 1-32, 34, 35, 61-63   |
| A         | ABE, K. et al. Primary structure and cell-type specific expression of a gustatory G protein-coupled receptor related to olfactory receptors. J. Biol. Chem. 05 June 1993, Vol. 268, No. 16, pages 12033-12039. | 1-32, 34, 35, 61-63   |

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *B* earlier document published on or after the international filing date  | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *I* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

08 OCTOBER 1999

Date of mailing of the international search report

04 NOV 1999

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL T. BRANNOCK

Telephone No. (703) 308-0196

 JOYCE BRIDGERS  
 PARALEGAL SPECIALIST  
 CHEMICAL MATRIX

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/17099

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-32, 34, 35, 61-63

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/17099

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-32, 34, 35, 61-63, drawn to nucleic acids, vectors, host cells, polypeptides, and methods for making host cells and polypeptides.

Group II, claim(s) 33, drawn to an antibody.

Group III, claim(s) 36-60, drawn to methods of identifying modulators of sensory signal transduction.

## The effect of the sweetness inhibitor 2-(4-methoxyphenoxy)propanoic acid (sodium salt) (Na-PMP) on the taste of bitter-sweet stimuli

Claire Johnson, Gordon G. Birch and Douglas B. MacDougall

*Department of Food Science and Technology, Food Studies Building,  
University of Reading, Whiteknights, P.O. Box 226, Reading,  
Berks RG6 2AP, UK*

**Abstract.** The effect of the sweetness inhibitor 2-(4-methoxyphenoxy)propanoic acid (sodium salt) (Na-PMP) on the taste and temporal properties of a range of bitter-sweet stimuli was determined using a trained sensory panel. Na-PMP was found to be an effective inhibitor of the sweetness response of all stimuli tested, reducing both sweetness intensity and persistence. The inhibitor was found to be specific to sweet taste, no reduction in bitterness intensity or persistence was observed at the concentrations of Na-PMP employed in this study. The results therefore do not support the claim of Fuller and Kurtz (1991), that Na-PMP is a potent bitterness inhibitor, but rather support the existence of two distinct receptor sites/loci in sweet and bitter chemoreception.

### Introduction

There has recently been considerable commercial interest from the Food Industry in the development of taste modifiers or inhibitors that could be incorporated in foods at very low levels, e.g. less than 5% by weight, to improve overall acceptability.

The recent development of sweet and bitter taste inhibitors (Lindley and Rathbone, 1985; Barnett and Yarger, 1986; Roy *et al.*, 1991) has provided the chemoreception scientist involved in the study of the relationship between sweet and bitter tastes with a valuable tool.

Similarities in the structural requirements of molecules to elicit sweet and bitter tastes have revealed that the receptor mechanisms responsible for these tastes may be in some way related (Belitz *et al.*, 1979; Tamura *et al.*, 1990; Temussi *et al.*, 1991; Roy, 1992). Based on the Shallenberger–Acree–Kier model for sweetness, three chemical groups have been identified as important for sweetness. These correspond to AH (an electrophile), B (a nucleophile) and X (a hydrophobic group). For bitterness, only the AH and X components have been found to be a requirement, but a B group may also be present. In addition, Temussi *et al.* (1991) have proposed that sweet and bitter receptors are twinned, a reverse binding of the AH, B groups for sweetness results in bitterness.

There are many other experimental observations linking sweetness and bitterness chemoreception. Examples include the common phenomenon that a slight alteration of sweet-tasting molecules, particularly with respect to spatial arrangement or orientation of functional groups, can result in molecules being rendered bitter or tasteless (Birch *et al.*, 1977; Belitz *et al.*, 1979; Temussi *et al.*, 1991); e.g. L-aspartyl L-phenylalanine methyl ester (Aspartame) is intensely sweet, while the D-form is perceived as bitter. Also, this is true for the unusual monosaccharide D-mannose, where the anomer  $\alpha$ -D-mannose is sweet, while  $\beta$ -D-mannose is perceived as bitter (Stewart *et al.*, 1971).



Sweet and bitter taste inhibitors can be used in chemoreception research to study the possible link between structural requirements of sweetness/bitterness induction and sweetness/bitterness inhibition. The taste inhibitors have been described as 'structurally deficient' when regarding the AH,B tenet. The sweetness inhibitor Na-PMP [2-(4-methoxyphenoxy)propanoic acid, sodium salt] developed by Tate & Lyle plc., and the aryl urea sulfonic acids patented by NutraSweet Ltd, as sweetness and bitterness inhibitors, have both been found to lack a putative AH moiety.

These striking structural relationships between sweet and bitter molecules, and sweet/bitter taste inhibitors strongly suggest a high degree of commonality within sweet and bitter chemoreception.

Although the naturally-occurring sweetness inhibitor gymnemic acid is known to be specific only to sweet taste (Lawless, 1979), the possibility that new synthetic sweetness inhibitors could also be used as potential bitterness inhibitors has recently been investigated by Bioresearch (Roy, 1992). A subsequent patent was released regarding the use of certain commercially available sweetness inhibitors in the reduction of bitterness in foodstuffs (Fuller and Kurtz, 1991). However, that investigation employed relatively high levels of inhibitor addition, some of which would exceed the levels permitted by F.E.M.A. (Flavour and Essence Manufacturer's Association) for commercial products, so it is by no means certain that the bitterness reductions reported in the patent can be directly applied to a commercial food product.

In this study, the effect of addition of the extremely potent sweetness inhibitor Na-PMP, up to levels of 200 ppm, on the taste properties of bitter-sweet stimuli is investigated using a time-intensity procedure. These inhibitor levels correspond to those permitted by F.E.M.A. for use in foods (maximum level permitted = 150 ppm) and, therefore, should indicate the type of taste inhibition that could be expected in a commercial product containing the inhibitor.

### Materials and methods

A panel of nine subjects, experienced in Quantitative Descriptive Analysis (QDA) (Stone *et al.*, 1974) of bitter-sweet stimuli, was recruited from the technical staff and postgraduate students of the Department of Food Science and Technology, University of Reading (two male and seven females, aged 21–56 years).

Further training in the use of the Sensory Unit for Measuring Flux (SMURF) (Birch and Munton, 1981) scale to measure intensity and persistence of sweet and bitter tastes was given.

Two trays of five samples were presented at each session. The first tray of samples were scored for sweetness, the second for bitterness. A reference, corresponding to an intensity of 5, i.e. the mid-point of the SMURF scale, was provided at the beginning of each test. For sweetness assessment, a glucose reference was prepared at 4% (wt/vol) and for bitterness a 0.0005% (wt/vol) solution of quinine sulfate was supplied.

Samples, labelled with three-figure random codes, were presented in random order. The sample size was 7 ml. Assessors were asked to rinse their mouths thoroughly between samples with the mineral water provided. Each sample was assessed on three separate occasions.

The stimuli investigated were glucose, mannose, saccharin, acesulfam-K and a




Fig. 1. Typical time-intensity (TI) curve, illustrating TI parameters of interest.

glucose/quinine mixture ('Equimix'). Glucose was obtained from BDH Chemicals, Poole, Dorset, UK (AnaLar grade); D-mannose was obtained from Aldrich Chemical Co. Ltd., Gillingham, UK (99% purity, mixture of anomers) and subsequently recrystallised seven times from methanol, final mp = 133°C,  $[\alpha]_D = +14.2^\circ$  at equilibrium, to improve purity; saccharin (sodium salt) was obtained from Sigma Chemical Co., Poole, Dorset, UK; acesulfam-K (Sunett®) was obtained from Hoechst, Frankfurt, Germany, and quinine sulfate was obtained from Fisons Scientific Ltd., Loughborough, UK.

Solutions were prepared with distilled water, at least 6 h prior to tasting, to allow mutarotational equilibrium to be established.

The concentrations of glucose and mannose solutions investigated were 8% (wt/vol) and quinine sulfate was prepared at 0.0010% (wt/vol). Saccharin and acesulfam-K solutions were prepared at 0.05% (wt/vol) and 0.1% (wt/vol), respectively. The glucose/quinine 'Equimix' was prepared with 8% (wt/vol) glucose and 0.0010% (wt/vol) quinine sulfate.

Five levels of the sweetness inhibitor Na-PMP were investigated: 0, 25, 50, 100 and 200 ppm (parts per million) for each stimulus, with three replicates per assessor.

The SMURF curves obtained were parameterised into several sensory attributes of interest (see Figure 1).

Curve parameters were analysed using Generalised Procrustes Analysis (GPA), using Procrustes PC version 2 (Oliemans Punter and Partners) and the GPA transformed parameters were subsequently analysed by Three-way Analysis of Variance (ANOVA) using MINITAB version 8 PC (MINITAB Inc.).

GPA is a multivariate analysis procedure that allows matching of different assessor matrix configurations of the same samples. The analysis involves transformation to a common origin, rotation/reflection of axes and possibly an isotropic scale change, so that individual configurations can be matched to a consensus (Arnold and Williams, 1986).

GPA transformation of time-intensity data is a useful tool in reducing assessor variation, e.g. different salivary flow rates, different use of scale or reaction times, that could obscure sample differences.

### Results and discussion

Tables I–IV list the main effects of the study following three-way ANOVA of the GPA transformed data for sweetness intensity, sweetness persistence, bitterness intensity and bitterness persistence, respectively.

Table I. Three-way ANOVA table of sweetness intensity of GPA-transformed data

| Source         | Degrees of freedom | Sum of squares | Mean square | F-ratio | P     |
|----------------|--------------------|----------------|-------------|---------|-------|
| Assessor       | 8                  | 0.5558         | 0.0695      | 0.560   | 0.807 |
| Stimulus       | 4                  | 0.0000         | 0.0000      | 0.000   | 1.000 |
| Na-PMP Conc.   | 4                  | 278.09         | 69.523      | 564.4   | 0.000 |
| Ass*Sti        | 32                 | 2.2228         | 0.0695      | 0.560   | 0.975 |
| Ass*Na-PMP     | 32                 | 6.6173         | 0.2068      | 1.680   | 0.013 |
| Sti*Na-PMP     | 16                 | 13.937         | 0.8711      | 7.070   | 0.000 |
| Ass*Sti*Na-PMP | 128                | 13.826         | 0.1080      | 0.880   | 0.813 |
| Error          | 450                | 55.427         | 0.1232      |         |       |
| Total          | 674                | 370.67         |             |         |       |

Table II. Three-way ANOVA table of sweetness persistence of GPA-transformed data

| Source         | Degrees of freedom | Sum of squares | Mean square | F-ratio | P     |
|----------------|--------------------|----------------|-------------|---------|-------|
| Assessor       | 8                  | 0.1198         | 0.0150      | 0.110   | 0.999 |
| Stimulus       | 4                  | 0.0000         | 0.0000      | 0.000   | 1.000 |
| Na-PMP Conc.   | 4                  | 18.661         | 4.6654      | 34.4    | 0.000 |
| Ass*Sti        | 32                 | 0.4793         | 0.0150      | 0.110   | 1.00  |
| Ass*Na-PMP     | 32                 | 5.3709         | 0.1678      | 1.240   | 0.177 |
| Sti*Na-PMP     | 16                 | 2.1687         | 0.1355      | 1.000   | 0.455 |
| Ass*Sti*Na-PMP | 128                | 16.715         | 0.1306      | 0.960   | 0.592 |
| Error          | 450                | 60.9648        | 0.1355      |         |       |
| Total          | 674                |                |             |         |       |

Table III. Three-way ANOVA table of bitterness intensity of GPA-transformed data

| Source         | Degrees of freedom | Sum of squares | Mean square | F-ratio | P     |
|----------------|--------------------|----------------|-------------|---------|-------|
| Assessor       | 8                  | 0.000          | 0.0000      | 0.000   | 1.000 |
| Stimulus       | 4                  | 0.0000         | 0.0000      | 0.000   | 1.000 |
| Na-PMP Conc.   | 4                  | 48.987         | 12.246      | 31.06   | 0.000 |
| Ass*Sti        | 32                 | 0.0000         | 0.0000      | 0.000   | 1.000 |
| Ass*Na-PMP     | 32                 | 28.189         | 0.8809      | 2.230   | 0.000 |
| Sti*Na-PMP     | 16                 | 9.9058         | 0.6191      | 1.570   | 0.073 |
| Ass*Sti*Na-PMP | 128                | 80.057         | 0.6191      | 1.590   | 0.000 |
| Error          | 450                | 177.44         | 0.3943      |         |       |
| Total          | 674                | 344.58         |             |         |       |

GPA transformation was successful in removing assessor variation which can often obscure subtle, but important effects in human perceptual studies.

The Na-PMP was found to be an extremely potent sweetness inhibitor. Figures 2

Table IV. Three-way ANOVA table of bitterness persistence of GPA-transformed data

| Source         | Degrees of freedom | Sum of squares | Mean square | F-ratio | P     |
|----------------|--------------------|----------------|-------------|---------|-------|
| Assessor       | 8                  | 0.0000         | 0.0000      | 0.0000  | 1.000 |
| Stimulus       | 4                  | 0.0000         | 0.0000      | 0.0000  | 1.000 |
| Na-PMP Conc.   | 4                  | 6.5947         | 1.6487      | 12.130  | 0.000 |
| Ass*Sti        | 32                 | 0.0000         | 0.0000      | 0.0000  | 1.000 |
| Ass*Na-PMP     | 32                 | 4.9665         | 0.1552      | 1.1400  | 0.275 |
| Sti*Na-PMP     | 16                 | 1.2138         | 0.0759      | 0.5600  | 0.914 |
| Ass*Sti*Na-PMP | 128                | 27.3792        | 0.2139      | 1.5700  | 0.000 |
| Error          | 450                | 61.1405        | 0.1355      |         |       |
| Total          | 674                | 101.294        |             |         |       |




Fig. 2. The effect of increasing Na-PMP concentration on the perceived sweetness intensity of bitter-sweet stimuli.




Fig. 3. The effect of increasing Na-PMP concentration on the perceived sweetness persistence of bitter-sweet stimuli.

and 3 show the effect of increasing Na-PMP concentration on sweetness intensity and sweetness persistence, respectively. The Na-PMP was found to be an effective sweetness inhibitor for all sweeteners studied, although slight differences in the magnitude of the inhibitory effect between sweeteners were observed by a significant stimulus \*Na-PMP Conc. interaction for sweetness intensity. This interaction, however, was not found to be a significant effect regarding sweetness persistence, which suggests sweetness intensity and persistence are controlled by separate mechanisms. This is in agreement with previous observations (Birch, 1981). The observation that Na-PMP is a highly specific sweetness inhibitor, effective for both carbohydrate and artificial sweeteners, suggests the existence of a unique receptor site for all sweeteners. This would also be consistent with possible structural variants of a central receptor which would be capable of distinguishing qualitative differences between sweeteners (Lindley, 1991), or at least some commonality in sweet taste reception and transduction mechanisms for different molecular classes of sweet-tasting compounds.

The Na-PMP was found to have no bitterness inhibitory power at the concentrations used in this study; in fact, bitterness intensity and persistence were found to increase




Fig. 4. The effect of increasing Na-PMP concentration on the perceived bitterness intensity of bitter-sweet stimuli.

with increasing Na-PMP concentration. Significant interactions were observed for assessor \*Na-PMP for bitterness intensity and assessor \*Na-PMP\* stimulus for both bitterness intensity and persistence, which suggests small perceptual differences between assessors, but these effects are only minor compared to the main effect of Na-PMP on bitterness. Figures 4 and 5 show the effect of increasing Na-PMP concentration on bitterness intensity and persistence, respectively. The increase in perceived bitterness intensity and persistence is in agreement with that expected by release from mixture suppression, an effect which has been previously observed by Lawless (1979) in a study of the effect of the sweetness inhibitor gymnemic acid on the taste of bitter-sweet mixtures.

The results of the bitterness study therefore do not support the patent of Fuller and Kurtz (1991), who have claimed Na-PMP and related methoxyphenoxy alkanolic acids are potent bitterness inhibitors. However, in that previous study, levels of Na-PMP incorporated into foods were greatly in excess of levels studied here. At such high levels, up to 5% wt/wt, such a bitterness inhibitory effect might be anticipated, although it is doubtful whether the inhibitory effect could be described as pertaining to a potent




Fig. 5. The effect of increasing Na-PMP concentration on the perceived bitterness persistence of bitter-sweet stimuli.

bitterness inhibitor. The bitterness inhibitory effect in that previous study then, could be regarded as similar to that observed by the addition of low levels of sucrose to bitter stimuli, which is known to depress the intensity of bitterness perceived (Lawless, 1979; Pangborn, 1960). Incorporation of Na-PMP in food formulations has been permitted by F.E.M.A. up to 150 ppm, which precludes the potential use of Na-PMP as a potent bitter inhibitor, as no bitterness inhibitory effect was observed in this study at such levels.

The results of this study support the existence of two distinct receptor sites/loci of receptor site in sweet and bitter chemoreception.

The experimental data suggest a competitive mechanism for sweetness inhibition by Na-PMP, as suggested previously by Lindley (1991). It is unclear whether the Na-PMP blocks the sweet stimulus at the receptor site or at a point further along the sweetness transduction cascade, although a ligand-receptor interaction would appear most likely (Lindley, 1991; Roy, 1992). Na-PMP shows some structural similarities to the sweetener dulcin, as can be seen in Figure 6.

A competitive mechanism of inhibition involving a ligand-receptor interaction assumes that the inhibitor molecule accedes and preferentially binds to the receptor site in a similar way to a tastant molecule.




Fig. 6. Structural analogy between Na-PMP and the sweetener Dulcin.

Occupation of the sweetness receptor site by Na-PMP would also be expected to prevent binding of bitter molecules if sweet and bitter receptors are twinned as has been suggested by Temussi *et al.* (1991). As bitterness was found to increase with addition of Na-PMP in this experiment, this suggests that a separate and distinct bitter receptor site must also exist for bitter tastants.

The interesting observation of a slight increase in bitterness intensity and persistence of quinine sulfate with increasing concentrations of Na-PMP, may suggest a role for Na<sup>+</sup> in quinine taste reception. This would be in agreement with Kinammon (1988) who reported that Na<sup>+</sup>- and K<sup>+</sup>-sensitive ion channels were strongly linked to bitter taste transduction mechanisms. An alternative explanation could be that the inhibitor molecule 'primes' the bitter receptor site, and may enhance quinine binding to the receptor, in a manner possibly analogous to the hypothesis of bitter taste amplification by the von Ebner's gland protein suggested by Spielman *et al.* (1991).

#### Acknowledgements

We thank SERC for an appeal award in support of this work and ECRO and the Research Board of the University of Reading are thanked for travel grants. We also acknowledge the kind donation of 2-(4-methoxyphenoxy)propanoic acid (sodium salt) (Na-PMP) from Dr M.G.Lindley (LinTech Ltd).

#### References

- Arnold, G.M. and Williams, A.A. (1986) The use of generalised procrustes techniques in sensory analysis. In Piggott, J.R. (ed.), *Statistical Procedures in Food Research*. Elsevier Applied Science, London, pp. 233–253.
- Barnett, R.E. and Yarger, R.G. (1986) Sweetening composition and process for modifying the sweetness perception of a foodstuff, European Patent, EP 0132 444 B1.
- Belitz, H.D., Chen, W., Jugel, H., Treleano, R., Wieser, H., Gasteiger, J. and Marsili, M. (1979) Sweet and bitter compounds: structure-taste relationship. In Boudreau, J.C. (ed.), *Food Taste Chemistry*. American Chemical Society, New York, pp. 93–131.
- Birch, G.G. (1981) A molecular approach to intensity/time phenomena in sugar sweetness. In Cagan, R.H. and Kare, M.R. (eds), *Biochemistry of Taste and Olfaction*. Academic Press, New York, pp. 163–173.
- Birch, G.G. and Munton, S.L. (1981) Use of the 'SMURF' in taste analysis. *Chem. Senses*, 6, 45–52.
- Birch, G.G., Lee, C.K. and Ray, A. (1977) The chemical basis of bitterness in sugar derivatives. In Birch, G.G., Brennan, J.G. and Parker, K.J. (eds), *Sensory Properties of Foods*. Applied Science, London, pp. 101–111.
- Fuller, W.D. and Kurtz, R.J. (1991) Ingestibles containing substantially tasteless sweetness inhibitors as bitter



- taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers, World Patent Co-operation Treaty, WO 91/18523.
- Kinammon, S.C. (1988) Taste transduction: a diversity of mechanisms. *TINS*, 11, 49.
- Lawless, H.T. (1979) Evidence for neural inhibition in bittersweet taste mixtures. *J. Comp. Physiol. Psychol.*, 93, 538–547.
- Lindley, M.G. (1991) Phenoxyalkanoic acid sweetness inhibitors. In Walters, D.E., Orthoefer, F.T. and DuBois, G.E. (eds), *Sweeteners: Discovery, Molecular Design and Chemoreception*. American Chemical Society, New York, pp. 251–260.
- Lindley, M.G. and Rathbone, E.B. (1985) Method of modifying taste, GB Patent, GB 2 157 148 A.
- Pangborn, R.M. (1960) Taste interrelationships. *Food Res.*, 25, 245.
- Roy, G.M. (1992) Bitterness: reduction and inhibition. *Trends Fd Sci. Tech.*, 3, 85.
- Roy, G., Culbertson, C., Muller, G. and Nagarajan, S. (1991) Novel N-(Sulfomethyl)-N'-Arylureas, World Patent Co-operation Treaty, WO 90/11695.
- Speilman, A.I., D'Abundo, S., Lin, H.C., Chuiari, F. and Turner, G. (1991) Abstract No. 144 ACHEMS 1991 Abstracts, The Thirteenth Annual Meeting of the Association for the Chemoreception Sciences, Sarasota, Florida.
- Stewart, R.A., Carrioco, C.K., Webster, R.L. and Steinhardt, R.G. (1971) Taste perception of alpha-D-mannose and beta D-mannose. *Nature*, 234, 220.
- Stone, H., Sidel, J., Woolsey, A. and Singleton, R.C. (1974) Sensory evaluation by quantitative descriptive analysis. *Fd Technol.*, 28, 24–34.
- Tamura, M., Mori, N., Miyoshi, T., Koyama, S., Kohri, H. and Okai, H. (1990) Practical debittering using model peptides and related compounds. *Agric. Biol. Chem.*, 54, 41–51.
- Temussi, P.A., Lelj, F. and Tancredi, T. (1991) Structure-activity relationship of sweet molecules. In Walters, D.E., Orthoefer, F.T. and DuBois, G.E. (eds), *Sweeteners: Discovery, Molecular Design, and Chemoreception*. American Chemical Society, New York, pp. 143–161.

Received on February 23, 1994; accepted on May 9, 1994



# A candidate taste receptor gene near a sweet taste locus

Jean-Pierre Montmayeur, Stephen D. Liberles, Hiroaki Matsunami and Linda B. Buck

Howard Hughes Medical Institute, Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115, USA

Correspondence should be addressed to L.B.B. ([lbuck@hms.harvard.edu](mailto:lbuck@hms.harvard.edu))

The mechanisms underlying sweet taste in mammals have been elusive. Although numerous studies have implicated G proteins in sweet taste detection, the expected G protein-coupled receptors have not been found. Here we describe a candidate taste receptor gene, T1r3, that is located at or near the mouse *Sac* locus, a genetic locus that controls the detection of certain sweet tastants. T1r3 differs in amino acid sequence in mouse strains with different *Sac* phenotypes ('tasters' versus 'nontasters'). In addition, a perfect correlation exists between two different T1r3 alleles and *Sac* phenotypes in recombinant inbred mouse strains. The T1r3 gene is expressed in a subset of taste cells in circumvallate, foliate and fungiform taste papillae. In circumvallate and foliate papillae, most T1r3-expressing cells also express a gene encoding a related receptor, T1r2, raising the possibility that these cells recognize more than one ligand, or that the two receptors function as heterodimers.

The initial step in taste perception is the detection of tastants by taste cells, which are clustered in taste buds on the tongue and other parts of the mouth<sup>1</sup>. On the tongue, taste buds are grouped in circumvallate, foliate and fungiform taste papillae, which have distinct locations. Taste cells are depolarized by tastants, leading to the transmission of signals to the brain via gustatory nerve fibers that contact taste cells within the taste buds<sup>2</sup>.

Mammals can distinguish five taste qualities: sweet, sour, bitter, salty and umami (glutamate taste). Biochemical and electrophysiological studies indicate that the detection of salty and sour tastants is mediated by ion channels<sup>3</sup>. In contrast, sweet, bitter and umami taste transduction are likely to involve G protein-coupled receptors (GPCRs)<sup>3</sup>. A role for the taste-specific G protein, gustducin, in bitter and sweet taste is further suggested by the finding that mice lacking gustducin have deficits in the detection of both bitter and sweet tastants<sup>4</sup>.

Consistent with these observations, GPCRs that function as taste receptors, or that are likely to do so, have now been identified for both glutamate and bitter tastants<sup>5</sup>. A splice variant of the brain metabotropic glutamate receptor 4 (taste-mGluR4)<sup>6</sup> is expressed in taste cells, and, appropriate to the chemical diversity of bitter compounds, there is a family of approximately 25 candidate bitter receptors<sup>7,8</sup> (T2Rs), several of which have been shown to recognize bitter compounds<sup>9</sup>. Although a sweet taste receptor has been identified in *Drosophila*<sup>10</sup>, a mammalian sweet receptor has not yet been found. The functions of two other GPCRs expressed in mammalian taste cells, T1R1 and T1R2, are not yet known, but their subcellular location suggests that they function as taste receptors<sup>11</sup>.

Several genetic loci that have been identified in mouse or human control sensitivity to bitter or sweet compounds<sup>12</sup>. One of these, the *Sac* locus, governs the sensitivity of mice to certain sweet tastants, including sucrose and the artificial sweetener, saccharin<sup>13–18</sup>. C57BL/6J (B6) mice ('tasters') prefer water that contains 1.6 mM saccharin (or 50 mM sucrose) to water that does not<sup>14</sup>. In contrast, DBA/2J (D2) mice ('nontasters') exhibit this preference only at higher concentrations of the sweet tastants

(8 mM saccharin)<sup>13–19</sup> and even then, the preference is less pronounced. At higher concentrations, saccharin and sucrose also elicit greater responses in gustatory fibers of B6 than D2 (or other nontaster) mice<sup>17,20</sup>.


Previous studies showed that some T2r genes are located at or near genetic loci that control sensitivity to bitter tastes<sup>7,8</sup>. To explore whether the mouse *Sac* locus might similarly contain a gene encoding a sweet taste receptor, we searched the syntenic region of the human genome for genes encoding GPCRs. Using this approach, we identified T1r3, a gene encoding a GPCR that is expressed in a subset of taste cells in mouse. Chromosomal mapping studies using both a radiation hybrid panel and recombinant inbred strains showed that T1r3 is closely linked to the *Sac* locus on mouse chromosome 4. Sequence analyses of T1r3 in *Sac* taster versus nontaster strains further revealed allelic differences among mouse strains that could result in differences in *Sac* phenotype. Surprisingly, *in situ* hybridization studies showed that T1R3 is expressed in the same taste cells as T1R2, a related receptor, raising the possibility that the two receptors function as heterodimers or that these cells recognize more than one ligand.

## RESULTS

### Identification of a candidate taste receptor, T1R3

To investigate whether *Sac* phenotypes might result from polymorphisms in a sweet receptor gene, we first asked whether there is a gene that encodes a GPCR in the vicinity of the *Sac* locus. The *Sac* locus maps near the distal end of mouse chromosome 4 at about 83 cM from the centromere<sup>13–15,17,18</sup>. Using The Jackson Laboratory Mouse Informatics database, we determined that the corresponding region in human is at chromosome 1p36.

To examine whether there is a gene encoding a GPCR at 1p36, we first used the NCBI human genome sequence database to search for genes in this region that encode receptors related to other GPCRs<sup>8</sup>. We found none in the finished sequence database. However, in the draft sequence database (htgs), we found two BAC clones (AC026283 and AL139287) that overlapped with



**Fig. 1.** T1R3 differs in mice with different *Sac* phenotypes. The deduced protein sequences of hT1R3 and the mT1R1, mT1R2 and mT1R3 of C57BL/6J (B6) mice are aligned with those of the mT1R3s of DBA/2J (D2) and SWR/J (SW) mice. Predicted signal sequences are boxed, amino acids present in all the proteins are shaded in gray, and the seven potential transmembrane domains characteristic of GPCRs are indicated by horizontal bars and Roman numerals. Amino acid differences in mT1R3 in mice that differ in *Sac* phenotype are shaded in black. B6 mice are tasters, D2 mice are nontasters, and SW mice have an intermediate *Sac* phenotype. B6 and D2 mT1R3s differ at 6 positions (residues 55, 60, 61, 371, 706 and 855). SWR/J (SW) mice have the same amino acid as B6 mice at T1R3 positions 55 and 60, but the same as D2 mice at the other positions except at residues 261 and 692, where they differ from both B6 and D2 mice.

that between mT1R1 and hT1R1 (74%). All of the receptors shown have an extremely long N terminal extracellular domain (NTD), which, by analogy with the structurally related mGluRs, may be involved in ligand binding<sup>25,26</sup>.

In previous studies, we obtained evidence that alternative RNA splicing generates mT1R2 variants that differ in the NTD (J.-P. M. & L.B.B., unpublished data). We found that all three T1Rs appear to be encoded by 6 exons, 5 of which encode the NTD. However, RT-PCR amplification of mT1r3 and mT1r1 cDNAs encoding NTD segments did not yield PCR products of different sizes, suggesting that variants of T1R3 and T1R1 similar to those seen for T1R2 are not produced (data not shown). As reported for rat T1r1 and T1r2 (ref. 11), probes prepared from segments encoding membrane-spanning parts of mT1r1, mT1r2 and mT1r3 hybridized to single bands in Southern blots of restriction-enzyme-digested mouse genomic DNA (data not shown), suggesting the absence of closely related genes.

### The mT1r3 gene maps close to the *Sac* locus


The presence of hT1r3 at human chromosome 1p36 suggested that the mT1r3 gene would be in the corresponding region of mouse chromosome 4, near the *Sac* locus. To investigate this issue, we used the T31 radiation hybrid panel<sup>27</sup> to map the chromosomal location of mT1r3 (Fig. 2). We also mapped the locations of the mT1r1 and mT1r2 genes with this panel. To refine the order of markers in the distal region of chromosome 4 beyond what was currently available, we also mapped the locations of other markers in this region (*Dv1*<sup>28</sup>; *Gnb1*, ref. 29; *D4Smh6b*<sup>30</sup>; *D18346*, ref. 31 and *V2r2*, ref. 23). Several other markers previously mapped in this region using the T31 panel are also shown in Fig. 2.

These experiments showed that the mT1R3 gene is indeed located near the end of chromosome 4, close to the *Sac* locus (Fig. 2). Previous mapping studies indicate that the *Sac* locus is located on chromosome 4 in a region distal to *D4Smh6b*<sup>15</sup>. More recent studies position *Sac* in an approximately 2.6-cM

contigs (NT\_004384/NT\_002209) assigned to chromosome 1p36, and that contained a gene encoding a potential taste receptor. This receptor, 'hT1R3,' is related to the putative taste receptors T1R1 and T1R2 (Fig. 1). Although we also identified another gene at 1p36 that encodes a novel GPCR (as well as one encoding a serotonin receptor), further studies indicated that it is not expressed in taste tissue (data not shown).

We next isolated the mouse ortholog of hT1R3. Using degenerate primers, we first amplified a fragment of the mT1r3 gene from mouse genomic DNA. Consistent with the expression of T1r3 in taste tissue, using this fragment as probe, we were able to isolate two T1r3 cDNA clones from a cDNA library prepared from mouse circumvallate and foliate taste papillae. *In situ* hybridization experiments verified that the T1r3 gene is expressed in mouse taste cells (see below).

In Fig. 1, the deduced sequences of mT1R3 and hT1R3 are aligned with mT1R1 and mT1R2 sequences<sup>11</sup> that we obtained from cDNA clones. mT1R3 is related to mT1R1 (32% amino acid identity) and mT1R2 (30%) as well as the calcium sensing receptor<sup>21</sup> (29%) and the V2R family of candidate pheromone receptors<sup>22-24</sup> (28% maximum identity). Amino acid identity between mT1R3 and hT1R3 (72%) is similar to



segment, and in a location distal to *D4Mit256* and proximal to *D18346* (ref. 31). Similarly to *Sac*, *T1r3* mapped in a location distal to both *D4Smh6b* and *D4Mit256* and proximal to *D18346*. As in previous studies, *mT1r1* and *mT1r2* also mapped to the distal region of chromosome 4 (ref. 11; N. Ryba, personal communication). However, whereas *Sac* and *mT1r3* are both distal to *D4Smh6b*<sup>15</sup>, *mT1r1* and *T1r2* are both proximal to this marker (Fig. 2). This is consistent with a report that *mT1r1* is in a location about 5 cM proximal to *Sac*<sup>31</sup>.

#### Polymorphisms in the coding region of the *T1r3* gene

To investigate whether differences in *mT1r3* could be responsible for *Sac* phenotypes, we compared the sequences of *mT1r3* cDNAs amplified from B6 (taster) and D2 (nontaster) mice (Fig. 1). These experiments revealed six amino acid changes in *T1r3* in D2 compared to B6 mice. Four changes (T55A, I60T, P61L, R371Q) are located in the NTD, one (I706T) is at the end of transmembrane domain 4, and one (G855E) is in the C terminal cytoplasmic domain. The first three amino acid differences are located near residues that are altered in several defective forms of the calcium sensing receptor<sup>32</sup>. One or more differences in *T1r3* in this region in B6 versus D2 mice may similarly affect the function of *T1r3*.

We also examined whether there are differences in *mT1r1*, *mT1r2* or *Gnb1* in B6 versus D2 mice by comparing cDNAs amplified from taste tissue of the two strains. *Gnb1* (which maps near the *Sac* locus; Fig. 2) encodes the G protein beta-1 subunit, which is expressed in taste cells, and is therefore a possible candidate for a *Sac* locus gene<sup>29</sup>. We found that the coding regions of both the *T1r1* and *Gnb1* genes are identical in B6 and D2 mice. We identified several nucleotide differences in B6 versus D2 *T1r2* genes, two resulting in changes in the NTD (Fig. 1), but the chromosomal location of the *T1r2* gene excluded a role for these changes in *Sac* phenotype. We obtained further evidence against a role for *Gnb1* in *Sac* phe-

Fig. 2. The *mT1r3* gene is located near the *Sac* locus on mouse chromosome 4. Right, results of chromosome mapping studies conducted with the T31 radiation hybrid mapping panel, with relative distances shown in centirays (cR; see scale bar). The distal region of mouse chromosome 4 displayed is indicated on the chromosome 4 diagram at left. The locations of *T1r1*, *T1r2*, *T1r3*, *Gnb1*, *Dvl*, and *V2r2*, *D18346* and the *D4Smh6b* marker were mapped in the present studies; selected other markers that were mapped previously in other studies are shown for reference. Data for the anchor loci was obtained from The Jackson Laboratory Mouse Radiation Hybrid Database (<http://www.jax.org/resources/documents/cmdata/rhmap/4data.html>). All marker names should be italic but are in plain text for legibility. The *Sac* locus has been mapped distal to *D4Smh6b*. *T1r3* also mapped distal to *D4Smh6b*, whereas *Gnb1* mapped to the same location as *D4Smh6b*, and *T1r1* and *T1r2* both mapped proximal to it.

notype by *in situ* hybridization experiments, which failed to reveal any difference in the level or patterning of expression of *Gnb1* mRNAs in B6 versus D2 mice (data not shown).


#### *T1r3* alleles and *Sac* phenotypes are correlated

Previous studies determined the *Sac* phenotypes of recombinant inbred (RI) strains derived from crosses between B6 and D2 mice (BXD/Ty strains)<sup>14</sup>. To determine whether individual RI strains have the B6 or D2 *T1r3* allele, we used DNA from each RI strain in PCR reactions with primers that would amplify only the B6 or D2 allele (Fig. 3). The 3' end of the 3' primers matched sequence-encoding amino acids 60 and 61 in one or the other allele. Taking advantage of a *DraIII* site in only the D2 allele at this site (because of the amino acid 60 codon), we also amplified a larger *T1r3* DNA segment containing this region from each RI strain DNA, and then digested the segment with *DraIII*.

These experiments revealed a perfect correlation between *Sac* phenotypes and *T1r3* alleles (Fig. 3). All of the taster RI strains gave a PCR product with only the B6-specific primer, and all of the nontaster strains yielded a product with only the D2-specific primer. Moreover, *DraIII* cleaved all of the *T1r3* gene segments amplified from nontaster DNAs, but none of those obtained from taster DNAs. In contrast, similar studies of *T1r2* alleles showed a correlation with the *Sac* phenotype in only 16 of 21 RI strains (Fig. 3). Additional experiments using primers matching only one allele of *V2r2* showed a correlation in only 18 of 21 strains (Fig. 3), whereas allelic primers for *D18346* (ref. 31) gave results identical to the *T1r3* primers (data not shown), consistent with its location proximal to *V2r2*. These results indicated that *T1r3* is located 0–5.3 cM ( $p = 0.05$ ) from the *Sac* locus between *D4Smh6b* and *V2r2*<sup>15</sup>.

These results are consistent with those obtained using the radiation hybrid mapping panel, which placed *T1r3* in the same ~2.6-cM segment of chromosome 4 as the *Sac* locus between *D4Mit256* and *D18346* (ref. 31). In summary, the order of markers determined from the RI strains was *D4Smh6b–Sac–T1r3/Dvl–D18346–V2r2*; in the higher resolution radiation hybrid map, the order was *D4Mit256–D4Smh6b–T1r3/Dvl–D18346–V2r2*. Studies of the *Sac* locus using F2 hybrids and partially congenic mouse strains indicate an order of *D4Mit256–Sac–D18346* (ref. 31). Thus, both *T1r3* and *Sac* are flanked proximally by *D4Mit256* and *D4Smh6b* and distally by *D18346* and *V2r2* (*D4Mit256–D4Smh6b–Sac–T1r3–D18346–V2r2*).

Using the same methods, we examined the DNAs of several other inbred mouse strains for which the *Sac* phenotypes are known<sup>14,19,33,34</sup> (Fig. 3). DNAs from 129/SvJ, Balb/cBy and C3H/HeJ mice, all of which are nontasters<sup>14,16</sup>, gave *T1r3* PCR products only with the D2-specific primer, whereas DNA from



**Fig. 3.** Polymorphisms in the T1r3 gene are correlated with Sac phenotypes. PCR with allele-specific primers and restriction enzyme digestion was used to examine mT1r3 and mT1r2 alleles in a series of recombinant inbred (RI) strains (1–32) and other inbred (B6–SW) mouse strains with known Sac phenotypes (+, taster; –, nontaster; +/-, intermediate taster) as previously determined by Lush<sup>14</sup>. Reaction products were electrophoresed on agarose gels with 100-bp ladder size markers (M). The primers and enzyme used and the gene analyzed in each row are indicated at left. A perfect correlation is seen between B6 and D2 mT1r3 alleles and Sac phenotypes in the RI strains, whereas the correlation is only partial for mT1r2 and V2r2 alleles. A perfect correlation was also seen between amplification with mT1r3 allele-specific primers and restriction enzyme digestion and the taster and nontaster Sac phenotypes of the other inbred strains, but an intermediate taster strain yielded mixed results.

C57BL/6By, a taster strain closely related to B6, gave a product with only the B6 primer. In addition, T1r3 segments amplified only from the first 3 strains were cleaved with DraIII, providing further evidence that the T1r3 of nontaster strains have the same amino acid as D2 mice at position 60.

SWR/J mice have an intermediate Sac phenotype and cannot be classified as either tasters or nontasters<sup>14</sup>. Using DNA from SWR/J mice, neither T1r3 allele-specific primer yielded a PCR product, even though digestion with DraIII indicated that this strain has the same amino acid as B6 at position 60. Sequence analysis of the SWR/J T1r3 gene showed that amino acid 60 is the same as in B6 mice, but amino acid 61 is the same as in D2 mice (Fig. 1). In addition, this strain has the same amino acid as B6 at position 55, but the same amino acids as D2 at positions 371, 706 and 855. It also differs from both B6 and D2 at positions 261 (R261C) and 692 (L692S). These findings are consistent with a role for T1R3 in Sac phenotypes.

#### The expression of T1r3 in taste cells

To examine the expression of the T1r3 gene in taste tissue, we hybridized mT1r3 cRNA probes (or mT1r1 or mT1r2 probes) to sections through circumvallate, foliate and fungiform taste papillae of both B6 and D2 mice. These studies showed that the mT1r3 gene is expressed in all three types of taste papillae (Fig. 4) as well as in taste buds on the palate (data

not shown). The T1r3 probe hybridized to approximately 24% of cells (55 of 229) in circumvallate papillae, 15% of cells (16/108) in fungiform and 14% of cells (33/239) in foliate papillae. In contrast, as previously reported in rat<sup>11</sup>, the mT1r2 gene appeared to be expressed mainly in circumvallate and foliate taste papillae, whereas the mT1r1 gene was expressed strongly only in fungiform papillae (Fig. 4). None of the probes hybridized to sections of the olfactory epithelium or vomeronasal organ (data not shown).


We next used two-color *in situ* hybridization to ask whether T1R3 is expressed in the same cells as the taste-specific G protein, gustducin. In sections of circumvallate and foliate papillae, mT1r3 and gustducin probes hybridized largely to separate populations of taste cells (Fig. 5). Only about 10% of T1r3+ cells were also gustducin+ and only about 10% of gustducin+ cells were T1r3+ in circumvallate papillae. In foliate papillae, ~19% of T1r3+ cells were also gustducin+ and vice versa. Previous studies in rat indicate a similarly small overlap between cells expressing gustducin versus T1r1 or T1r2 (ref. 11). These results suggested that most taste cells that express T1R3 do not express gustducin. However, a low level of gustducin expression in the remaining T1r3+ cells could not be excluded.

We then compared the expression of T1r3 in individual cells with that of T1r1 and T1r2. Surprisingly, 98% of circumvallate taste cells that hybridized to the T1r3 probe also hybridized to the T1r2 probe. In addition, all T1r2+ cells were also T1r3+. In preliminary experiments, analysis of a few fungiform taste cells expressing the T1r3 gene similarly suggested that a proportion of those cells may coexpress the T1r1 gene, but further experiments are needed to clarify this issue. The finding that T1r3 and T1r2 genes are expressed in the same cells is in striking contrast to previous observations that T1r1 and T1r2 genes are predominantly expressed in different taste papillae, and that only a small percentage of T1r2+ foliate taste cells coexpress T1r1 (ref. 11).

#### DISCUSSION

The results presented here identify T1R3 as a candidate taste receptor in mouse and human, possibly a receptor for sweet tastants. First, consistent with previous studies implicating G proteins in sweet taste transduction<sup>1,3</sup>, T1R3 is a member of the GPCR superfamily that is expressed in a subset of taste cells in the mouth. Second, the mT1r3 gene is located at or near the Sac locus, a mouse genetic locus that controls sensitivity to certain

**Fig. 4.** The pattern of expression of T1r3 differs from that of T1r1 and T1r2. Sections of circumvallate (CV), foliate (Fol), and fungiform (Fun) taste papillae of C57BL/6J (B6) or DBA/2J (D2) mice were hybridized with digoxigenin-labeled mT1r1, mT1r2, mT1r3 or gustducin cRNA probes. The T1r3 probe labeled taste cells in taste buds of all three types of papillae, whereas the T1r1 probe predominantly labeled taste cells in fungiform papillae and the T1r2 probe labeled cells in circumvallate and foliate, but rarely in fungiform papillae. No significant differences were seen in the extent or patterning of labeling in B6 versus D2 mice. Scale bar, 50  $\mu$ m.





**Fig. 5.** T1r3 is coexpressed with T1r2, but not gustducin. Sections of B6 circumvallate papillae were hybridized simultaneously with a fluorescein-labeled T1r3 probe and a digoxigenin-labeled T1r3, T1r2 or gustducin (gust) probe. The digoxigenin-labeled probe was revealed with Alexa 488 (green), and the fluorescein-labeled probe, with HNPP/fast red (red). Each row shows red and green signals obtained from the same field and an overlay in which doubly labeled cells are yellow. The results indicate that most taste cells that express T1R3 or T1R2 express both receptors, whereas T1R3 and gustducin are primarily expressed in different cells. Scale bar, 50  $\mu$ m.


sweet tastants<sup>13–15,17,18</sup>. And finally, there are amino acid differences in T1R3 in Sac taster, nontaster and intermediate taster mice that could affect the function of T1R3 and thereby account for differences in Sac phenotype.

Null mutant mice lacking gustducin show deficiencies in the detection of both sweet and bitter tastants<sup>4</sup>. This suggests that gustducin may be expressed by many taste cells that recognize sweet tastants. In contrast, we detected gustducin in only approximately 10% of T1R3-expressing taste cells in the circumvallate papillae and approximately 20% of those in the foliate papillae. There are several possible explanations for this apparent discrepancy. One is that T1r3 is not a sweet receptor gene and that Sac phenotypes are determined by another gene, for example, a transcription factor gene that controls the expression of a sweet receptor. Indeed, the 2.6-cM chromosomal segment to which Sac is mapped undoubtedly contains numerous genes. Another possible explanation is that many T1R3-expressing cells express a low level of gustducin that was not detectable by the *in situ* hybridization methods used in our studies. Yet another possibility is that some cells that detect sweet tastants do express gustducin, whereas others do not. Consistent with this idea, the ability to detect sweet tastants is reduced, but not eradicated in gustducin null mutant mice<sup>4</sup>. In addition, there is biochemical evidence for the coupling of bitter taste receptors, but not sweet taste receptors, to gustducin<sup>3,9,35,36</sup>.

Our studies also argue against an involvement of T1R1, T1R2 or Gnb1 in Sac phenotypes. We found that T1R1 and Gnb1 both have identical sequences in the Sac taster and nontaster mouse strains B6 and D2. In addition, *in situ* hybridization indicated that the levels and patterning of expression of T1r1 and Gnb1 genes are the same in taster and nontaster mice. Moreover, consistent with one previous report<sup>31</sup>, we found that the T1r1 gene maps at a distance from the Sac locus on mouse chromosome 4, proximal to a marker (*D4Smh6b*) that is, in turn, proximal to the Sac locus and the mT1r3 gene. Although we identified differences in T1R2 in taster and nontaster mice, we found that the T1r2 gene is located even further from the Sac locus than the T1r1 gene, excluding T1R2 from a role in Sac phenotype.

Surprisingly, we found that the T1r3 gene is coexpressed with the T1r2 gene in many taste cells. Our studies indicated that nearly all circumvallate and foliate taste cells that express T1R3 or T1R2 express both receptors. In fungiform papillae, preliminary experiments suggested that T1R3 might similarly be coexpressed with T1R1, at least in some cells. This raises the possibility that, like the structurally-related GPCR, GABA<sub>B</sub><sup>37</sup>, T1R3 is expressed as a heterodimer with T1R2 or T1R1. Another possibility is that the T1Rs function separately, perhaps each recognizing one or more different ligands. Finally, the receptors might exist as both homodimers and heterodimers. This scheme could conceivably explain how sucrose and saccharin can stimulate different signal transduction cascades in a single taste cell<sup>38</sup>.

As in previous studies with rat T1R1 and T1R2 (ref. 11, 39), we were unable to obtain functional expression of any of the



mouse T1Rs in heterologous cells. Although functional expression has been obtained by attaching a short N terminal segment of rhodopsin to the N termini of some T2Rs<sup>9</sup>, this approach was unsuccessful with the T1Rs, including when T1R3 was coexpressed with T1R1 or T1R2, and when receptors or pairs of receptors were coexpressed with various G proteins. The cells expressing these receptors did not respond to saccharin, other sweeteners, or other tastants that were tested, including several bitter tastants and glutamate. Similar difficulties have been encountered in expressing most other types of chemosensory receptors, including V1Rs, V2Rs and most odorant receptors. As for those receptors, the functions of T1R3 and the other two T1Rs remain to be defined.

How many sweet receptors are there? Sweet taste chemicals include sugars, certain amino acids and proteins, and several artificial sweeteners with differing chemical structures, which suggests that there might be multiple different sweet receptors<sup>40</sup>. Although some modeling studies predict the existence of a single sweet receptor<sup>41,42</sup>, the existence of at least several different sweet receptors is supported by a number of human taste perception studies, as well as electrophysiological studies in rodents<sup>43–45</sup>. In humans, cross-adaptation studies indicate that perceptual adaptation to one sweet tastant does not necessarily result in an inability to detect another sweet tastant<sup>46,47</sup>. In mice, single taste cells can be depolarized by multiple different sugars, but adaptation of a cell to one of those sugars does not result in adaptation to all of the others<sup>48</sup>. Although these studies suggest that there is more than one sweet receptor, the actual number of receptors that detect sweet compounds remains to be determined.

If T1R3 is indeed a sweet receptor, are there additional receptors that recognize sweet tastants? One possibility is that all three T1Rs are sweet receptors. In this scenario, the different T1Rs could recognize different or partially overlapping sets of sweet tastants. Alternatively, different homodimers or heterodimers of the T1Rs could have different specificities. There might also be additional members of the T1R family that are involved in sweet taste, but that are not yet identified. Another possibility is that some members of the T2R family recognize sweet rather than bitter tastants. Future studies should ultimately reveal whether one or both of these receptor families is indeed involved in sweet taste or whether sweet taste involves yet another receptor family.





## METHODS

**Cloning of T1Rs.** The sequence of hT1R3 was deduced from BAC clones AC026283 and AL139287 (NCBI). Pairs of degenerate primers (SW1/SW14 or SW7/SW14) matching hT1R3 were used to amplify a T1r3 gene segment from mouse genomic DNA. PCR products of the expected size were cloned (TA Topo-4 vector; Invitrogen, Carlsbad, California), sequenced, and used to screen (55°C) a mouse (C57BL/6J) circumvallate and foliate taste papillae cDNA library prepared in λZAPII (Stratagene, La Jolla, California)<sup>49</sup>. One 2.8-kb cDNA clone encoded most of mT1R3. cDNAs encoding the remaining coding region were obtained from the cDNA library by PCR. (SW1, 5'-CA(C/T)(C/T)CITG(C/T)TG(C/T)T(A/T)(C/T)GAITG-(C/T)(A/G)TIGA(C/T)TG-3'; SW7, 5'-CCI(A/T)CICICGCIAGITG-(T/C)TTIGCI-CA(A/G)CA-3'; SW14, 5'-A(A/G)IA(A/G)IGCICCC-AT(C/T)TGACICGIGG-3').

We obtained mT1r1 and mT1r2 cDNAs in previous studies in which we used PCR with degenerate primers matching various known GPCRs to search for candidate taste receptors (unpublished data). A 220-bp fragment obtained with one primer pair (LB2/LB4) was cloned and sequenced, revealing a segment of the mT1r2 coding region. Two ESTs with related, but distinct sequences (W18663, mouse; AA853697, human) that encoded part of T1R1 were identified in the dbest database. Using the T1r2 cDNA and T1r1 ESTs (Genome Systems, Palo Alto, California) as probes, clones encoding mT1R1 and mT1R2 were isolated from the taste tissue cDNA library. The sequences of these cDNAs are identical to those reported<sup>11,31</sup>. (LB2, 5'-AA(C/T)CTICIGIAIAA(C/T)TA(C/T)-(A/T)A(C/T)GA(A/G)G(G/C)IAA-3'; LB4, 5'-GGICGI(G/C)(A/T)-IAGIATIA(C/T)(A/G)TA(A/G)CA(C/T)TTIGG-3').

**Chromosome mapping.** DNA segments were amplified from the RH T31 mapping panel (Research Genetics, Huntsville, Alabama), using conditions specified by the manufacturer, and primers matching the genes encoding mT1R1 (20R9/43R9; 186-bp fragment), mT1R2 (31R7/33R7; 776-bp fragment), mT1R3 (15TR3/11TR3; 357-bp fragment), *Dvl* (3Dvl-1/4Dvl-1; 191-bp fragment), *V2r2* (7VR2/8VR2; 302-bp fragment), the microsatellite marker *D4Smh6b*, the *STS D18346* (1D18346/5D18346; 170-bp fragment) and *Gnb1* (7TB1/8TB1; 371-bp fragment). Results were interpreted using The Jackson Laboratory Mouse Radiation Hybrid database (<http://www.jax.org/resources/documents/cmdata/rhmap/rhsubmit.html>). Advice on data interpretation was provided by L. Rowe (The Jackson Laboratory, Bar Harbor, Maine). Primer sequences used in the mapping are as follows: 20R9, 5'-CCACTCTGAGTGGCGGC-3'; 43R9, 5'-GACCCGCCACCTTCAGCC-3'; 31R7, 5'-AGCTGCCATG-TGACAGC-3'; 33R7, 5'-ACATATAGCGCCATCACC-3'; 15TR3, 5'-TTCCATCACTACAGATGAC-3'; 11TR3, 5'-GCTCAGGCAGCC TGTGAG-3'; 3Dvl-1, 5'-GGCCGCATTGAGCCGGGC-3'; 4Dvl-1, 5'-CCCTGTCTGGGACACGAT-3'; 7VR2, 5'-ACTTACAAATGGAC-AGC-3'; 8VR2, 5'-CTTTGTCTAGAACATTG-3'; 7TB1, 5'-GATGATGGC ATGCGCTGTG-3'; 8TB1, 5'-ATTGGACCAACCCAAAC-3'; 1D18346, 5'-TGTCGCGAGTGTGGAACTA-3'; 5D18346, 5'-AAGGGAT-GTCCAGGGTAGAG-3'.

**Analyses of inbred mouse strains.** Fifty nanograms of genomic DNA from BXD/Ty RI or other inbred strains (The Jackson Laboratory, Bar Harbor, Maine) were used in PCR reactions: 94°/1 min, 54°/1 min, 72°/2 min + 6 s extension for 38 cycles. For T1R3, a 5' primer matching both B6 and D2 alleles (38TR3) was used in combination with a 3' primer specific for B6 (BXD-B6) or D2 (BXD-DBA) allele. Alternatively, primers matching both alleles (38TR3/36TR3) were used and the resulting 265-bp product was digested with DraII. For T1R2, a 5' primer matching both B6 and D2 alleles (5R7) was used in combination with a 3' primer specific for the B6 allele (BXD.B6TR2). Alternatively, primers matching both alleles (5R7/53R7) were used and the 529 bp product was digested with SphI, which cleaves only the D2 allele, because of a difference in the codon for amino acid 352. For V2r2 ('V2r2<sup>23</sup>'), a 5' primer matching both B6 and D2 alleles (5VR2) was used with a B6-allele specific primer (6VR2). Primer sequences used for allele typing are as follows: 38TR3, 5'-AGGGGACTACAT-ACCTGGG-3'; BXD-B6, 5'-GAGAACCTGTTCACAGGGA-3'; BXD-DBA, 5'-GAGAACCTGTTCACAGGGA-3'; 36TR3, 5'-TTGATC-TCCCTCCACAGCC-3'; 5R7, 5'-CCTGTACAGAACCAAC-3'; BXD.B6Tr2, 5'-GGATACTCTGGCTTGTGCG-3'; 53R7, 5'-GATAGAC-

GATTTGCTTCG-3'; 5VR2, 5'-AGATGTCCAGATAATAAA-3'; 6VR2, 5'-AGGTGACCTGGTCCGGAT-3'.

To compare mT1R sequences in different strains, cDNA was prepared (First Strand cDNA Synthesis Kit, Life Technologies, Rockville, Maryland) from RNA isolated from circumvallate, foliate and fungiform taste papillae of adult mice<sup>49</sup>, and used in PCR reactions to specific with specific primers. The RT-PCR products<sup>49</sup> were isolated from agarose gels and then directly sequenced using specific primers<sup>50</sup>.

**In situ hybridization.** Sixteen-micrometer sections of adult mouse taste papillae were hybridized (58°C) to digoxigenin-labeled cRNA probes prepared from cloned segments of cDNAs encoding mT1R1 (nt 1881–2564 plus nt 29–1778), mT1R2 (nt 152–1754), mT1R3 (nt 1–1700), or gustducin (fragment encoding amino acids 22–328). Experiments were done as described previously<sup>23</sup>, except that, following fixation, sections were treated with 0.2 M HCl (8 min, RT) and then proteinase K (10 µg/ml; Roche, Indianapolis, Indiana; 10 min, RT). Sections were counterstained with Hoechst 33258 (Sigma, St. Louis, Missouri) to visualize taste cell nuclei and determine the percentage of taste cells labeled with individual probes<sup>23</sup>.

Two-color *in situ* hybridization experiments used the same conditions, with the following modifications. Twelve-micrometer sections of taste papillae were hybridized to both digoxigenin- and fluorescein-labeled (Roche) cRNA probes<sup>23</sup>. Following hybridization, sections were incubated with tyramide blocking reagent (NEN, Boston, Massachusetts), incubated with peroxidase-anti-digoxigenin and alkaline phosphatase-anti-fluorescein antibodies (Roche; 1 h, RT), washed, incubated with tyramide-biotin (NEN, Boston, Massachusetts; 10 min), washed, incubated with streptavidin-Alexa 488 (Molecular Probes, Eugene, Oregon) in the dark (30 min), washed, treated with HNPP/ Fast Red alkaline phosphatase substrate (Roche), and then counterstained with Hoechst 33258 (ref. 23; Sigma). Reagents were used essentially as recommended by the manufacturers. Sections mounted in gelvatol were examined using confocal microscopy (Biorad, Herts, England).

## ACKNOWLEDGEMENTS

We thank L. Rowe at The Jackson Laboratory for suggestions and contributions to the chromosome mapping studies. We also thank C. Gao for technical assistance, and members of the Buck lab, in particular, C. Neophytou, for help, comments and discussions throughout this project. This work was supported by the Howard Hughes Medical Institute, grants from the National Institutes of Health (L.B.B.), and fellowship support from the Alice and Joseph Brook Fund (J.-P.M.), the Naito Foundation (H.M.), and the Japan Society for the Promotion of Science (H.M.). GenBank accession number for mT1R1, mT1R2 and mT1R3 are AF337039–41

RECEIVED 19 MARCH; ACCEPTED 28 MARCH 2001

1. Lindemann, B. Taste reception. *Physiol. Rev.* 76, 718–766 (1996).
2. Herness, M. S. & Gilbertson, T. A. Cellular mechanisms of taste transduction. *Annu. Rev. Physiol.* 61, 873–900 (1999).
3. Gilbertson, T., Damak, S. & Margolskee, R. The molecular physiology of taste transduction. *Curr. Opin. Neurobiol.* 10, 519–527 (2000).
4. Wong, G. T., Gannon, K. S. & Margolskee, R. F. Transduction of bitter and sweet taste by gustducin. *Nature* 381, 796–800 (1996).
5. Kinnamon, S. A plethora of taste receptors. *Neuron* 25, 507–510 (2000).
6. Chaudhari, N., Landin, A. & Roper, S. A metabotropic glutamate receptor variant functions as a taste receptor. *Nat. Neurosci.* 3, 113–119 (2000).
7. Adler, E. et al. A novel family of mammalian taste receptors. *Cell* 100, 693–702 (2000).
8. Matsunami, H., Montmayeur, J.-P. & Buck, L. A family of candidate taste receptors in human and mouse. *Nature* 404, 601–604 (2000).
9. Chandrasekar, J. et al. T2Rs function as bitter taste receptors. *Cell* 100, 703–711 (2000).
10. Ishimoto, H., Matsumoto, A. & Tanimura, T. Molecular identification of a taste receptor gene for trehalose in *Drosophila*. *Science* 289, 116–119 (2000).
11. Hoon, M. A. et al. Putative mammalian taste receptors: a class of taste-specific GPCRs with distinct topographic selectivity. *Cell* 96, 541–551 (1999).
12. Reed, D. Gene mapping for taste related phenotypes in human and mice. *Appetite* 35, 189–190 (2000).
13. Fuller, J. Single-locus control of saccharin preference in mice. *J. Hered.* 65,



- 33–36 (1974).
14. Lush, I. The genetics of tasting in mice: VI. Saccharin, acesulfame, dulcin and sucrose. *Genet. Res.* 53, 95–99 (1989).
15. Lush, I., Hornigold, N., King, P. & Stoye, J. The genetics of tasting in mice. VII. Glycine revisited, and the chromosomal location of Sac and Soa. *Genet. Res.* 66, 167–174 (1995).
16. Capeless, C. & Whitney, G. The genetic basis of preference for sweet substances among inbred strains of mice: Preference ratio phenotypes and the alleles of the Sac and dpa loci. *Chem. Senses* 20, 291–298 (1995).
17. Bachmanov, A. *et al.* Sucrose consumption in mice: major influence of two genetic loci affecting peripheral sensory responses. *Mamm. Genome* 8, 545–548 (1997).
18. Blizard, D., Kotlus, B. & Frank, M. Quantitative trait loci associated with short-term intake of sucrose saccharin and quinine solutions in laboratory mice. *Chem. Senses* 24, 373–385 (1999).
19. Belknap, J. *et al.* Single locus control of saccharin intake in BXD/Ty recombinant inbred (RI) mice: some methodological implications for RI strain analysis. *Behav. Genet.* 22, 81–100 (1992).
20. Frank, M. & Blizard, D. Chorda tympani responses in two inbred strains of mice with different taste preferences. *Physiol. Behav.* 67, 287–297 (1999).
21. Brown, E. *et al.* Cloning and characterization of an extracellular  $Ca^{2+}$ -sensing receptor from bovine parathyroid. *Nature* 366, 575–580 (1993).
22. Herrada, G. & Dulac, C. A novel family of putative pheromone receptors in mammals with a topographically organized and sexually dimorphic distribution. *Cell* 90, 763–773 (1997).
23. Matsunami, H. & Buck, L. A multigene family encoding a diverse array of putative pheromone receptors in mammals. *Cell* 90, 775–784 (1997).
24. Ryba, N. J. & Tirindelli, R. A new multigene family of putative pheromone receptors. *Neuron* 19, 371–379 (1997).
25. Takahashi, K., Tsuchida, K., Tanabe, Y., Masu, M. & Nakanishi, S. Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. *J. Biol. Chem.* 268, 19341–19345 (1993).
26. Kunishima, N. *et al.* Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* 407, 971–977 (2000).
27. McCarthy, L. *et al.* A first-generation whole genome-radiation hybrid map spanning the mouse genome. *Genome Res.* 7, 1153–1161 (1997).
28. Eicher, E. & Shown, E. Molecular markers that define the distal end of mouse autosomes 4, 13, and 19 and the sex chromosomes. *Mamm. Genome* 4, 226–229 (1993).
29. Danciger, M., Farber, D., Peyser, M. & Kozak, C. The gene for the beta-subunit of retinal transducin (Gnb-1) maps to distal mouse chromosome 4, and related sequences map to mouse chromosomes 5 and 8. *Genomics* 6, 428–435 (1990).
30. Greenfield, A., Brown, S., Friedman, J. & Bahary, N. Mapping of clone D4Smh6b to the distal end of mouse chromosome 4. *Mouse Genome* 90, 94–95 (1992).
31. Li, X. *et al.* High-resolution genetic mapping of the saccharin preference locus (Sac) and the putative sweet taste receptor (T1R1) gene (*Gpr70*) to mouse distal Chromosome 4. *Mamm. Genome* 12, 13–16 (2001).
32. Bai, M. Structure and function of the extracellular calcium-sensing receptor. *Intl. J. Mol. Med.* 4, 115–125 (1999).
33. Pelz, W., Whitney, G. & Smith, J. Genetic influences on saccharin preference of mice. *Physiol. Behav.* 10, 263–265 (1973).
34. Ramirez, I. & Fuller, J. Genetic influence on water and sweetened water consumption in mice. *Physiol. Behav.* 16, 163–168 (1976).
35. Ruiz-Avila, L. *et al.* Coupling of bitter receptor to phosphodiesterase through transducin in taste receptor cells. *Nature* 376, 80–85 (1995).
36. Ming, D., Ruiz-Avila, L. & Margolskee, R. Characterization and solubilization of bitter-responsive receptors that couple to gustducin. *Proc. Natl. Acad. Sci. USA* 95, 8933–8938 (1998).
37. Marshall, F., Jones, K., Kaupmann, K. & Bettler, B. GABA<sub>B</sub> receptors—the first TTM heterodimers. *Trends Pharmacol. Sci.* 20, 396–399 (1999).
38. Bernhardt, S., Naim, M., Zehavi, U. & Lindemann, B. Changes in IP3 and cytosolic  $Ca^{2+}$  in response to sugars and non-sugar sweeteners in transduction of sweet taste in the rat. *J. Physiol. (Lond.)* 490, 325–336 (1996).
39. Gimelbrant, A., Haley, S. & McClintock, T. Olfactory receptor trafficking involves conserved regulatory steps. *J. Biol. Chem.* 276, 7285–7290 (2001).
40. Faurion, A., Salto, S. & MacLeod, P. Sweet taste involves several distinct receptor mechanisms. *Chem. Senses* 5, 107–121 (1980).
41. Glaser, D., Tinti, J.-M. & Nofre, C. Evolution of the sweetness receptor in primates. I. Why does all taste sweet in all prosimians and simians, and aspartame only in old world simians? *Chem. Senses* 20, 573–584 (1995).
42. Nofre, C., Tinti, J.-M. & Glaser, D. Evolution of the sweetness receptor in primates. II. Gustatory responses of non-human primates to nine compounds known to be sweet in man. *Chem. Senses* 21, 747–762 (1996).
43. Froloff, N., Faurion, A. & MacLeod, P. Multiple human taste receptor sites: a molecular modelling approach. *Chem. Senses* 21, 425–445 (1996).
44. Nimomyia, Y., Inoue, M., Imoto, T. & Nakashima, K. Lack of gurmarin sensitivity of sweet taste receptors innervated by the glossopharyngeal nerve in C57BL mice. *Am. J. Physiol.* 272, R1002–R1006 (1997).
45. Nimomyia, Y., Imoto, T. & Sugimura, T. Sweet taste response of mouse chorda tympani neurons: Existence of gurmarin-sensitive and -insensitive receptor components. *J. Neurophysiol.* 81, 3087–3091 (1999).
46. Schiffman, S., Cahn, H. & Lindley, M. Multiple receptor sites mediate sweetness: evidence from cross adaptation. *Pharmacol. Biochem. Behav.* 15, 377–388 (1981).
47. Froloff, N., Lloret, E., Martinez, J.-M. & Faurion, A. Cross-adaptation and molecular modelling study of receptor mechanisms common to four taste stimuli in humans. *Chem. Senses* 23, 197–206 (1998).
48. Tonosaki, K. & Funakoshi, M. Cross-adapted sugar responses in the mouse taste cell. *Comp. Biochem. Physiol.* 92A, 181–183 (1989).
49. Berghard, A. & Buck, L. Sensory transduction in vomeronasal neurons: evidence for G $\alpha$ o, G $\alpha$ i2, and adenylyl cyclase II as major components of a pheromone signalling cascade. *J. Neurosci.* 16, 909–918 (1996).
50. Malnic, B., Hirono, J., Sato, T. & Buck, L. B. Combinatorial receptor codes for odors. *Cell* 96, 713–723 (1999).